U.S. patent application number 15/430837 was filed with the patent office on 2017-06-01 for chimeric pestiviruses.
The applicant listed for this patent is ZOETIS SERVICES LLC. Invention is credited to Robert Gerard Ankenbauer, Yugang Luo, Siao-Kun Wan Welch, Ying Yuan.
Application Number | 20170151321 15/430837 |
Document ID | / |
Family ID | 41665513 |
Filed Date | 2017-06-01 |
United States Patent
Application |
20170151321 |
Kind Code |
A1 |
Luo; Yugang ; et
al. |
June 1, 2017 |
CHIMERIC PESTIVIRUSES
Abstract
The present invention relates to chimeric pestiviruses having
utility as immunogenic compositions and vaccines. Also described
herein are methods and kits for treating or preventing the spread
of bovine viral diarrhea virus infection, as well as methods and
kits for differentiating between vaccinated and wild-type infected
animals.
Inventors: |
Luo; Yugang; (Kalamazoo,
MI) ; Welch; Siao-Kun Wan; (Kalamazoo, MI) ;
Yuan; Ying; (Kalamazoo, MI) ; Ankenbauer; Robert
Gerard; (Portage, MI) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
ZOETIS SERVICES LLC |
Parsippany |
NJ |
US |
|
|
Family ID: |
41665513 |
Appl. No.: |
15/430837 |
Filed: |
February 13, 2017 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12624473 |
Nov 24, 2009 |
9567375 |
|
|
15430837 |
|
|
|
|
61173363 |
Apr 28, 2009 |
|
|
|
61119594 |
Dec 3, 2008 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 31/14 20180101;
G01N 33/6854 20130101; A61K 2039/5252 20130101; A61P 1/04 20180101;
C07K 16/1081 20130101; C12N 2770/24321 20130101; A61K 2039/552
20130101; A61P 1/12 20180101; C07K 14/005 20130101; A61K 39/12
20130101; A61K 2039/5256 20130101; C12N 2770/24322 20130101; A61K
2039/53 20130101; C12N 2770/24361 20130101; A61K 2039/525 20130101;
A61K 2039/5254 20130101; C12N 7/00 20130101 |
International
Class: |
A61K 39/12 20060101
A61K039/12; G01N 33/68 20060101 G01N033/68; C12N 7/00 20060101
C12N007/00; C07K 14/005 20060101 C07K014/005; C07K 16/10 20060101
C07K016/10 |
Claims
1. A chimeric pestivirus, wherein said chimeric pestivirus
comprises a bovine viral diarrhea virus which does not express its
homologous E.sup.rns protein, further wherein said chimeric
pestivirus expresses a heterologous E.sup.rns protein derived from
another pestivirus, or a natural, synthetic or genetic variant of
said heterologous E.sup.rns protein.
2. The chimeric pestivirus of claim 1, wherein the heterologous
E.sup.rns protein of said chimeric pestivirus, or the natural,
synthetic or genetic variant of said heterologous E.sup.rns
protein, is derived from a pestivirus selected from the group
consisting of a reindeer pestivirus, a giraffe pestivirus, and a
pronghorn antelope pestivirus.
3. The chimeric pestivirus of claim 1, wherein the heterologous
E.sup.rns protein of said chimeric pestivirus has at least one
E.sup.rns epitope which is not present in wild-type bovine viral
diarrhea virus.
4. The chimeric pestivirus of claim 1, wherein the heterologous
E.sup.rns protein of said chimeric pestivirus lacks at least one
E.sup.rns epitope which is present in wild-type bovine viral
diarrhea virus.
5. A culture of the chimeric pestivirus of claim 1.
6. A cell line or host cell comprising the chimeric pestivirus of
claim 1.
7. A polynucleotide molecule encoding for the chimeric pestivirus
of claim 1.
8. An immunogenic composition comprising the chimeric pestivirus of
claim 1, and a veterinarily-acceptable carrier.
9. The immunogenic composition of claim 8, wherein the
veterinarily-acceptable carrier is an adjuvant.
10. The immunogenic composition of claim 8, wherein said chimeric
pestivirus is live attenuated.
11. The immunogenic composition of claim 8, wherein said chimeric
pestivirus is inactivated.
12. The immunogenic composition of claim 8, further comprising one
or more additional antigens useful for treating or preventing the
spread of one or more additional pathogenic microorganisms in a
bovine.
13. An immunogenic composition comprising the polynucleotide
molecule of claim 7 and a veterinarily-acceptable carrier.
14. A vaccine comprising the chimeric pestivirus of claim 1 and a
veterinarily-acceptable carrier.
15. The vaccine of claim 14, wherein the veterinarily-acceptable
carrier is an adjuvant.
16. The vaccine of claim 14, wherein said chimeric pestivirus is
live attenuated.
17. The vaccine of claim 14, wherein said chimeric pestivirus is
inactivated.
18. A vaccine comprising the polynucleotide molecule of claim 7 and
a veterinary acceptable carrier.
19. The vaccine of claim 14, further comprising one or more
additional antigens useful for treating or preventing the spread of
one or more additional pathogenic microorganisms in a bovine.
20. A kit comprising, in at least one container, the vaccine of
claim 14.
21. A method of treating or preventing the spread of bovine viral
diarrhea virus infection, wherein the vaccine of claim 14 is
administered to an animal.
22. A method of vaccinating an animal, wherein a DIVA pestivirus
vaccine is administered to said animal, and wherein said DIVA
pestivirus vaccine comprises the chimeric pestivirus of claim 1,
further wherein said chimeric pestivirus has at least one E.sup.rns
epitope which is not present in wild-type bovine viral diarrhea
virus.
23. A method of vaccinating an animal, wherein a DIVA pestivirus
vaccine is administered to said animal, and wherein said DIVA
vaccine comprises the chimeric pestivirus of claim 1, further
wherein said chimeric pestivirus lacks at least one E.sup.rns
epitope which is present in wild-type bovine viral diarrhea
virus.
24. A method of differentiating between an animal vaccinated with
the vaccine of claim 14 and an animal infected with wild type
bovine viral diarrhea virus, wherein the animal vaccinated with
said vaccine generates antibodies to at least one E.sup.rns epitope
which is present in the chimeric pestivirus of said vaccine, but
which is not present in wild-type bovine viral diarrhea virus, said
method comprising the steps of: a) obtaining a serum sample from
the animals; b) assaying said samples for the presence or absence
of the antibodies; c) identifying the animal having said antibodies
as having been vaccinated with said vaccine; and d) identifying the
animal lacking said antibodies as having been infected with the
wild type BVDV.
25. A method of differentiating between an animal infected with
wild-type bovine viral diarrhea virus and an animal vaccinated with
the vaccine of claim 14, wherein the animal infected with wild type
bovine viral diarrhea virus generates antibodies to at least one
E.sup.rns epitope which is present in wild-type bovine viral
diarrhea virus, but which is not present in the chimeric pestivirus
of said vaccine, said method comprising the steps of: a) obtaining
a serum sample from the animals; b) assaying said samples for the
presence or absence of the antibodies; c) identifying the animal
having said antibodies as having been infected with the wild type
BVDV; and d) identifying the animal lacking said antibodies as
having been vaccinated with said vaccine.
26. A diagnostic kit for differentiating between an animal
vaccinated with a vaccine comprising the chimeric pestivirus of
claim 1 and an animal infected with wild type bovine viral diarrhea
virus, said kit comprising reagents capable of detecting antibodies
to at least one E.sup.rns epitope which is present in the chimeric
pestivirus of the vaccine, but which is not present in wild-type
bovine viral diarrhea virus.
27. A diagnostic kit for differentiating between an animal infected
with wild type bovine viral diarrhea virus and an animal vaccinated
with a vaccine comprising the chimeric pestivirus of claim 1, said
kit comprising reagents capable of detecting antibodies to at least
one E.sup.rns epitope which is present in wild-type bovine viral
diarrhea virus, but which is not present in the chimeric pestivirus
of the vaccine.
28. An antibody which recognizes an epitope of E.sup.rns which is
present in the chimeric pestivirus of claim 1, but which epitope is
not present in wild-type bovine viral diarrhea virus.
29. An antibody which recognizes an epitope present in wild-type
bovine viral diarrhea virus, but which epitope is not present in
the chimeric pestivirus of claim 1.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application is a continuation of U.S.
application Ser. No. 12/624,473, filed Nov. 24, 2009, an allowed
application, and claims the benefit under 35 U.S.C. 119(e) of U.S.
Provisional Application Nos. 61/119,594, filed Dec. 3, 2008, and
61/173,363, filed Apr. 28, 2009. The complete disclosure of each of
the aforementioned applications is incorporated by reference
herein, as if fully set forth.
FIELD OF THE INVENTION
[0002] The present invention relates to novel chimeric pestiviruses
and their use in immunogenic compositions and vaccines. It also
relates to methods and kits for treating or preventing the spread
of bovine viral diarrhea virus infection. The present invention
further relates to the use of the chimeric pestiviruses in methods
and kits for differentiating between vaccinated animals and animals
infected with a wild-type virus.
BACKGROUND
[0003] Pestiviruses, including bovine viral diarrhea virus (BVD
virus, or BVDV), have been isolated from several species of
animals, both domestic and wild. Identified hosts for BVDV include
buffalo, antelope, reindeer and various deer species, while unique
pestivirus species have been identified in giraffes and pronghorn
antelope. BVDV is a small RNA virus of the family Flaviviridae. It
is closely related to other pestiviruses which are the causative
agents of border disease in sheep and classical swine fever in
pigs. Recently a divergent pestivirus named Bungowannah pestivirus
was identified as an etiologic agent of fetal infection of piglets
in Australia.
[0004] Disease caused by BVDV particularly in cattle is widespread,
and can be economically devastating. BVDV infection in cattle can
result in breeding problems, and can cause abortions or premature
births. BVDV is capable of crossing the placenta of pregnant
cattle, and may result in the birth of persistently infected (PI)
calves that are immunotolerant to the virus and persistently
viremic for the rest of their lives. Infected cattle can also
exhibit "mucosal disease", characterized by elevated temperature,
diarrhea, coughing and ulcerations of the alimentary mucosa. These
persistently infected animals provide a source for dissemination of
virus within the herd for further outbreaks of mucosal disease and
are highly predisposed to infection with microorganisms responsible
for causing enteric diseases or pneumonia.
[0005] BVDV is classified into one of two biotypes. Those of the
"cp" biotype induce a cytopathic effect on cultured cells, whereas
viruses of non-cytopathic, or "ncp", biotype do not. In addition,
two major genotypes (type 1 and 2) are recognized, both of which
have been shown to cause a variety of clinical syndromes.
[0006] BVDV virions are 40 to 60 nm in diameter. The nucleocapsid
of BVDV consists of a single molecule of RNA and the capsid protein
C. The nucleocapsid is surrounded by a lipid membrane with two
glycoproteins anchored in it, E1 and E2. A third glycoprotein,
E.sup.rns, is loosely associated to the envelope. The genome of
BVDV is approximately 12.5 kb in length, and contains a single open
reading frame located between the 5' and 3' non-translated regions
(NTRs). A polyprotein of approximately 438 kD is translated from
this open reading frame, and is processed by cellular and viral
proteases into at least eleven viral structural and nonstructural
(NS) proteins (Tautz, et al., J. Virol. 71:5415-5422 (1997); Xu, et
al., J. Virol. 71:5312-5322 (1997); Elbers, et al., J. Virol.
70:4131-4135 (1996); and Wiskerchen, et al., Virology 184:341-350
(1991)). The genomic order of BVDV is p20/N.sup.pro, p14/C,
gp48/E.sup.rns, gp25/E1, gp53/E2, p54/NS2, p80/NS3, p10/NS4A,
p32/NS4B, p58/NS5A and p75/NS5B. The three envelope proteins,
gp48/E.sup.rns, gp25/E1 and gp53/E2, are heavily glycosylated.
E.sup.rns (formerly referred to as E0 or gp48) forms homodimers,
covalently linked by disulfides. The absence of a hydrophobic
membrane anchor region suggests that E.sup.rns is loosely
associated with the envelope. E.sup.rns induces high antibody
titers in infected cattle, but the antisera has limited
virus-neutralizing activity.
[0007] Among the BVDV vaccines currently available are those which
contain chemically-inactivated wild-type virus. These vaccines
typically require the administration of multiple doses, and result
in a short-lived immune response; they also do not protect against
fetal transmission of the virus. In sheep, a subunit vaccine based
on a purified E2 protein has been reported. Although this vaccine
appears to protect fetuses from becoming infected, protection is
limited to only the homologous strain of virus, and there is no
correlation between antibody titers and protection.
[0008] Modified live (ML) BVDV vaccines have been produced using
virus that has been attenuated by repeated passaging in bovine or
porcine cells, or by chemically-induced mutations that confer a
temperature-sensitive phenotype on the virus. A single dose of a
MLV BVDV vaccine has proven sufficient for providing protection
from infection, and the duration of immunity can extend for years
in vaccinated cattle. In addition, cross-protection has been
reported using MLV vaccines (Martin, et al., In "Proceedings of the
Conference of Research Workers in Animal Diseases", 75:183 (1994)).
However, existing MLV vaccines do not allow for the differentiation
between vaccinated and naturally-infected animals.
[0009] Thus, it is clear that a need exists for new vaccines for
controlling the spread of BVDV. Such a vaccine(s) could be
invaluable in future national or regional BVDV eradication
programs, and could also be combined with other cattle vaccines,
representing a substantial advance in the industry. A more
effective vaccine for controlling and monitoring the spread of BVDV
would be a "marked" vaccine. Such a vaccine could either contain an
additional antigenic determinant which is not present in wild-type
virus, or lack an antigenic determinant which is present in
wild-type virus. With respect to the former, vaccinated animals
mount an immune response to the "marker" immunogenic determinant,
while non-vaccinated animals do not. Through the use of an
immunological assay directed against the marker determinant,
vaccinated animals could be differentiated from non-vaccinated,
naturally-infected animals by the presence of antibodies to the
marker determinant. In the case of the latter strategy, animals
infected with the wild-type virus mount an immune response to the
marker determinant, while non-infected, vaccinated animals do not,
as a result of the determinant not being present in the marked
vaccine. Through the use of an immunological assay directed against
the marker determinant, infected animals could be differentiated
from vaccinated, non-infected animals. In both scenarios, by
culling out the infected animals, the herd could, over time, become
BVDV-free. In addition to the benefit of removing the threat of
BVDV disease, certification of a herd as BVDV-free has direct
freedom of trade economic benefits.
SUMMARY
[0010] In one embodiment, the present invention provides a chimeric
pestivirus, wherein said chimeric pestivirus comprises a bovine
viral diarrhea virus which does not express its homologous
E.sup.rns protein, further wherein said chimeric pestivirus
expresses a heterologous E.sup.rns protein derived from another
pestivirus, or a natural, synthetic or genetic variant of said
heterologous E.sup.rns protein.
[0011] In another embodiment, the present invention provides the
chimeric pestivirus as described above, wherein the heterologous
E.sup.rns protein of said chimeric pestivirus, or the natural,
synthetic or genetic variant of said heterologous E.sup.rns
protein, is derived from a pestivirus selected from the group
consisting of a reindeer pestivirus, a giraffe pestivirus, and a
pronghorn antelope pestivirus.
[0012] In a different embodiment, the present invention provides
the chimeric pestivirus as described above, wherein the
heterologous E.sup.rns protein of said chimeric pestivirus has at
least one E.sup.rns epitope which is not present in wild-type
bovine viral diarrhea virus.
[0013] In a separate embodiment, the present invention provides the
chimeric pestivirus as described above, wherein the heterologous
E.sup.rns protein of said chimeric pestivirus lacks at least one
E.sup.rns epitope which is present in wild-type bovine viral
diarrhea virus.
[0014] In one embodiment, the present invention provides a culture
of the chimeric pestivirus as described above.
[0015] In another embodiment, the present invention provides a cell
line or host cell comprising the chimeric pestivirus as described
above.
[0016] In yet another embodiment, the present invention provides a
polynucleotide molecule encoding for the chimeric pestivirus as
described above.
[0017] In a different embodiment, the present invention provides an
immunogenic composition comprising the chimeric pestivirus as
described above and a veterinarily-acceptable carrier.
[0018] In a separate embodiment, the present invention provides the
immunogenic composition as described above, wherein the
veterinarily-acceptable carrier is an adjuvant.
[0019] In yet another embodiment, the present invention provides
the immunogenic composition as described above, wherein said
chimeric pestivirus is live attenuated.
[0020] In still another embodiment, the present invention provides
the immunogenic composition as described above, wherein said
chimeric pestivirus is inactivated.
[0021] In a different embodiment, the present invention provides
the immunogenic composition as described above, further comprising
one or more additional antigens useful for treating or preventing
the spread of one or more additional pathogenic microorganisms in
an animal.
[0022] In a separate embodiment, the present invention provides an
immunogenic composition comprising the polynucleotide molecule
encoding for the chimeric pestivirus as described above and a
veterinarily-acceptable carrier.
[0023] In one embodiment, the present invention provides a vaccine
comprising the chimeric pestivirus as described above and a
veterinarily-acceptable carrier.
[0024] In another embodiment, the present invention provides the
vaccine as described above, wherein the veterinarily-acceptable
carrier is an adjuvant.
[0025] In a different embodiment, the present invention provides
the vaccine as described above, wherein said chimeric pestivirus is
live attenuated.
[0026] In yet another embodiment, the present invention provides
the vaccine as described above, wherein said chimeric pestivirus is
inactivated.
[0027] In still another embodiment, the present invention provides
the vaccine as described above, further comprising one or more
additional antigens useful for treating or preventing the spread of
one or more additional pathogenic microorganisms in an animal.
[0028] In a separate embodiment, the present invention provides a
vaccine comprising a polynucleotide molecule encoding for the
chimeric pestivirus as described above and a veterinary acceptable
carrier.
[0029] In one embodiment, the present invention provides a kit
comprising, in at least one container, a vaccine comprising the
chimeric pestivirus as described above.
[0030] In another embodiment, the present invention provides a
method of treating or preventing the spread of bovine viral
diarrhea virus infection, wherein a vaccine comprising the chimeric
pestivirus as described above is administered to an animal.
[0031] In a different embodiment, the present invention provides
method of vaccinating an animal, wherein a DIVA pestivirus vaccine
is administered to said animal, and wherein said DIVA pestivirus
vaccine comprises the chimeric pestivirus as described above,
further wherein said chimeric pestivirus has at least one E.sup.rns
epitope which is not present in wild-type bovine viral diarrhea
virus.
[0032] In a separate embodiment, the present invention provides
method of vaccinating an animal, wherein a DIVA pestivirus vaccine
is administered to said animal, and wherein said DIVA vaccine
comprises the chimeric pestivirus as described above, further
wherein said chimeric pestivirus lacks at least one E.sup.rns
epitope which is present in wild-type bovine viral diarrhea virus.
In yet another embodiment, the present invention provides method of
differentiating between an animal vaccinated with a vaccine
comprising the chimeric pestivirus as described above and an animal
infected with wild type bovine viral diarrhea virus, wherein the
animal vaccinated with said vaccine generates antibodies to at
least one E.sup.rns epitope which is present in the chimeric
pestivirus of said vaccine, but which is not present in wild-type
bovine viral diarrhea virus, said method comprising the steps of:
[0033] a) obtaining a serum sample from the animals; [0034] b)
assaying said samples for the presence or absence of the
antibodies; [0035] c) identifying the animal having said antibodies
as having been vaccinated with said vaccine; and [0036] d)
identifying the animal lacking said antibodies as having been
infected with the wild type BVDV.
[0037] In still another embodiment, the present invention provides
method of differentiating between an animal infected with wild-type
bovine viral diarrhea virus and an animal vaccinated with a vaccine
comprising the chimeric pestivirus as described above, wherein the
animal infected with wild type bovine viral diarrhea virus
generates antibodies to at least one E.sup.rns epitope which is
present in wild-type bovine viral diarrhea virus, but which is not
present in the chimeric pestivirus of said vaccine, said method
comprising the steps of: [0038] a) obtaining a serum sample from
the animals; [0039] b) assaying said samples for the presence or
absence of the antibodies; [0040] c) identifying the animal having
said antibodies as having been infected with the wild type BVDV;
and [0041] d) identifying the animal lacking said antibodies as
having been vaccinated with said vaccine.
[0042] In one embodiment, the present invention provides diagnostic
kit for differentiating between an animal vaccinated with a vaccine
comprising the chimeric pestivirus as described above and an animal
infected with wild type bovine viral diarrhea virus, said kit
comprising reagents capable of detecting antibodies to at least one
E.sup.rns epitope which is present in the chimeric pestivirus of
the vaccine, but which is not present in wild-type bovine viral
diarrhea virus.
[0043] In another embodiment, the present invention provides
diagnostic kit for differentiating between an animal infected with
wild type bovine viral diarrhea virus and an animal vaccinated with
a vaccine comprising the chimeric pestivirus as described above,
said kit comprising reagents capable of detecting antibodies to at
least one E.sup.rns epitope which is present in wild-type bovine
viral diarrhea virus, but which is not present in the chimeric
pestivirus of the vaccine.
[0044] In yet another embodiment, the present invention provides an
antibody which recognizes an epitope of E.sup.rns which is present
in the chimeric pestivirus as described above, but which epitope is
not present in wild-type bovine viral diarrhea virus.
[0045] In a different embodiment, the present invention provides an
antibody which recognizes an epitope present in wild-type bovine
viral diarrhea virus, but which epitope is not present in the
chimeric pestivirus as described above.
[0046] In another embodiment, a chimeric pestivirus as described
herein is used in the preparation of a medicament for the
prevention or treatment of infections caused by BVDV.
DETAILED DESCRIPTION
[0047] The following definitions may be applied to terms employed
in the description of embodiments of the invention. The following
definitions supercede any contradictory definitions contained in
each individual reference incorporated herein by reference.
[0048] Unless otherwise defined herein, scientific and technical
terms used in connection with the present invention shall have the
meanings that are commonly understood by those of ordinary skill in
the art. Further, unless otherwise required by context, singular
terms shall include pluralities and plural terms shall include the
singular.
[0049] The term "amino acid," as used herein, refers to naturally
occurring and synthetic amino acids, as well as amino acid analogs
and amino acid mimetics that function in a manner similar to the
naturally occurring amino acids. Naturally occurring amino acids
are those encoded by the genetic code, as well as those amino acids
that are later modified, for example, hydroxyproline,
carboxyglutamate, and O-phosphoserine. Stereoisomers (e.g., D-amino
acids) of the twenty conventional amino acids, unnatural amino
acids such as .alpha. and .alpha.-disubstituted amino acids,
N-alkyl amino acids, lactic acid, and other unconventional amino
acids may also be suitable components for polypeptides of the
present invention. Examples of unconventional amino acids include:
4-hydroxyproline, .gamma.-carboxyglutamate,
.epsilon.-N,N,N-trimethyllysine, .epsilon.-N-acetyllysine,
O-phosphoserine, N-acetylserine, N-formylmethionine,
3-methylhistidine, 5-hydroxylysine, .sigma.-N-methylarginine, and
other similar amino acids and imino acids.
[0050] Amino acid analogs refer to compounds that have the same
basic chemical structure as a naturally occurring amino acid, i.e.,
a carbon that is bound to a hydrogen, a carboxyl group, an amino
group, and an R group. Exemplary amino acid analogs include, for
example, homoserine, norleucine, methionine sulfoxide, and
methionine methyl sulfonium. Such analogs have modified R groups
(e.g., norleucine) or modified peptide backbones, but retain the
same essential chemical structure as a naturally occurring amino
acid. Amino acid mimetics refer to chemical compounds that have a
structure that is different from the general chemical structure of
an amino acid, but that function in a manner similar to a naturally
occurring amino acid.
[0051] Amino acids may be referred to herein by either their
commonly known three letter symbols or by the one-letter symbols
recommended by the IUPAC-IUB Biochemical Nomenclature
Commission.
[0052] The term "animal" as used herein, is meant to include any
animal that is susceptible to BVDV infections, including but not
limited to bovine, ovine, caprine and porcine species, both
domesticated and wild.
[0053] The term "antibody" or "antibodies", as used herein, refers
to an immunoglobulin molecule able to bind to an antigen by means
of recognition of an epitope. Antibodies can be a polyclonal
mixture or monoclonal. Antibodies can be intact immunoglobulins
derived from natural sources or from recombinant sources, or can be
immunoreactive portions of intact immunoglobulins. Antibodies can
exist in a variety of forms including, for example, as, Fv, Fab',
F(ab').sub.2, as well as in single chains.
[0054] The term "antigen" as used herein refers to a molecule that
contains one or more epitopes (linear, conformational or both) that
upon exposure to a subject will induce an immune response that is
specific for that antigen. The term "antigen" can refer to
attenuated, inactivated or modified live bacteria, viruses, fungi,
parasites or other microbes. The term "antigen" as used herein can
also refer to a subunit antigen, which is separate and discrete
from a whole organism with which the antigen is associated in
nature. The term "antigen" can also refer to antibodies, such as
anti-idiotype antibodies or fragments thereof, and to synthetic
peptide mimotopes that can mimic an antigen or antigenic
determinant (epitope). The term "antigen" can also refer to an
oligonucleotide or polynucleotide that expresses an antigen or
antigenic determinant in vivo, such as in DNA immunization
applications.
[0055] The terms "BVDV", "BVDV isolates" or "BVDV strains" as used
herein refer to bovine viral diarrhea viruses, including but not
limited to type I and type II, that consist of the viral genome,
associated proteins, and other chemical constituents (such as
lipids). A number of type I and type II bovine viral diarrhea
viruses are known to those skilled in the art and are available
through, e.g., the American Type Culture Collection (ATCC.RTM.).
The bovine viral diarrhea virus has a genome in the form of RNA.
RNA can be reverse transcribed into DNA for use in cloning. Thus,
references made herein to nucleic acid and bovine viral diarrhea
virus sequences encompass both viral RNA sequences and DNA
sequences derived from the viral RNA sequences.
[0056] The term "cell line" or "host cell", as used herein means a
prokaryotic or eukaryotic cell in which a virus can replicate
and/or be maintained.
[0057] The term "chimeric" or "chimera" as used herein means a
microorganism, for example a virus, containing genetic or physical
components derived from more than one progenitor.
[0058] The term "culture" as used herein means a population of
cells or microorganisms growing in the absence of other species or
types.
[0059] The term "DIVA" as used herein means a vaccine which is able
to differentiate infected from vaccinated animals.
[0060] An "epitope" is the specific site of the antigen which binds
to a T-cell receptor or specific antibody, and typically comprises
from about 3 amino acid residues to about 20 amino acid
residues.
[0061] The term "heterologous", as used herein, means derived from
a different species or strain.
[0062] The term "homologous", as used herein, means derived from
the same species or strain.
[0063] The term "immunogenic composition", as used herein, means a
composition that generates an immune response (i.e., has
immunogenic activity) when administered alone or with a
pharmaceutically acceptable carrier, to an animal. The immune
response can be a cellular immune response mediated primarily by
cytotoxic T-cells, or a humoral immune response mediated primarily
by helper T-cells, which in turn activates B-cells leading to
antibody production.
[0064] The term "pathogen" or "pathogenic microorganism" as used
herein means a microorganism--for example a virus, bacterium,
fungus, protozoan, or helminth--which is capable of inducing or
causing a disease, illness, or abnormal state in its host
animal.
[0065] The term "pestivirus" as used herein means a RNA virus from
the genus Pestivirus, of the family Flaviviridae. Pestiviruses
include, but are not limited to, BVDV (type 1 and type 2),
Classical Swine Fever Virus (CSFV), and Border Disease Virus (BDV),
as well as pestiviruses isolated from species such as wild boar,
buffalo, eland, bison, alpaca, pudu, bongo, various deer species,
giraffe, reindeer, chamois and pronghorn antelope (Vilcek and
Nettleton; Vet Microbiol. 116:1-12 (2006))
[0066] The term "polynucleotide molecule" as used herein means an
organic polymer molecule composed of nucleotide monomers covalently
bonded in a chain. DNA (deoxyribonucleic acid) and RNA (ribonucleic
acid) are examples of polynucleotides with distinct biological
function.
[0067] The terms "prevent", "preventing" or "prevention", and the
like, as used herein, mean to inhibit the replication of a
microorganism, to inhibit transmission of a microorganism, or to
inhibit a microorganism from establishing itself in its host. These
terms and the like as used herein can also mean to inhibit or block
one or more signs or symptoms of infection.
[0068] The term "therapeutically effective amount" as used herein
means an amount of a microorganism, or a subunit antigen, or
polypeptides, or polynucleotide molecules, and combinations
thereof, sufficient to elicit an immune response in the subject to
which it is administered. The immune response can comprise, without
limitation, induction of cellular and/or humoral immunity.
[0069] The terms "treat", "treating" or "treatment", and the like,
as used herein mean to reduce or eliminate an infection by a
microorganism. These terms and the like as used herein can also
mean to reduce the replication of a microorganism, to reduce the
transmission of a microorganism, or to reduce the ability of a
microorganism to establish itself in its host. These terms and the
like as used herein can also mean to reduce, ameliorate, or
eliminate one or more signs or symptoms of infection by a
microorganism, or accelerate the recovery from infection by a
microorganism.
[0070] The terms "vaccine" and "vaccine composition," as used
herein, mean a composition which prevents or reduces an infection,
or which prevents or reduces one or more signs or symptoms of
infection. The protective effects of a vaccine composition against
a pathogen are normally achieved by inducing in the subject an
immune response, either a cell-mediated or a humoral immune
response or a combination of both. Generally speaking, abolished or
reduced incidences of infection, amelioration of the signs or
symptoms, or accelerated elimination of the microorganism from the
infected subjects are indicative of the protective effects of a
vaccine composition. The vaccine compositions of the present
invention provide protective effects against infections caused by
BVDV.
[0071] The term "variant," as used herein, refers to a derivation
of a given protein and/or gene sequence, wherein the derived
sequence is essentially the same as the given sequence, but for
mutational differences. Said differences may be
naturally-occurring, or synthetically- or
genetically-generated.
[0072] The term "veterinarily-acceptable carrier" as used herein
refers to substances, which are within the scope of sound medical
judgment, suitable for use in contact with the tissues of animals
without undue toxicity, irritation, allergic response, and the
like, commensurate with a reasonable benefit-to-risk ratio, and
effective for their intended use.
[0073] The following description is provided to aid those skilled
in the art in practicing the present invention. Even so, this
description should not be construed to unduly limit the present
invention as modifications and variations in the embodiments
discussed herein can be made by those of ordinary skill in the art
without departing from the spirit or scope of the present inventive
discovery.
Viruses, Immunogenic Compositions, and Vaccines
[0074] The present invention provides immunogenic compositions and
vaccines comprising one or more chimeric pestiviruses, wherein said
chimeric pestiviruses comprise a bovine viral diarrhea virus which
does not express its homologous E.sup.rns protein, but wherein said
chimeric pestivirus expresses a heterologous E.sup.rns protein
derived from another pestivirus, or a natural, synthetic or genetic
variant of said heterologous E.sup.rns protein. The chimeric
pestivirus can be selected from, but is not limited to, the group
consisting of BVDV/reindeer pestivirus, BVDV/giraffe pestivirus,
and BVDV/pronghorn antelope pestivirus chimeras.
[0075] In one embodiment, the BVDV/giraffe chimeric pestivirus is
the strain deposited as UC 25547 with American Type Culture
Collection (ATCC.RTM.), 10801 University Boulevard, Manassas, Va.
20110-2209, USA, and given the ATCC.RTM. deposit designation of
PTA-9938. In one embodiment, the BVDV/pronghorn antelope chimeric
pestivirus is the strain deposited as UC 25548 with ATCC.RTM. and
given the ATCC.RTM. deposit designation of PTA-9939. In one
embodiment, the BVDV/reindeer chimeric pestivirus is the strain
deposited as UC 25549 with ATCC.RTM. and given the ATCC.RTM.
deposit designation of PTA-9940.
[0076] Chimeric pestiviruses of the present invention can be
propagated in cells, cell lines and host cells. Said cells, cell
lines or host cells may be for example, but not limited to,
mammalian cells and non-mammalian cells, including insect and plant
cells. Cells, cell lines and host cells in which chimeric
pestiviruses of the present invention may be propagated are readily
known and accessible to those of ordinary skill in the art.
[0077] The chimeric pestiviruses of the present invention can be
attenuated or inactivated prior to use in an immunogenic
composition or vaccine. Methods of attenuation and inactivation are
well known to those skilled in the art. Methods for attenuation
include, but are not limited to, serial passage in cell culture on
a suitable cell line, ultraviolet irradiation, and chemical
mutagenesis. Methods for inactivation include, but are not limited
to, treatment with formalin, betapropriolactone (BPL) or binary
ethyleneimine (BEI), or other methods known to those skilled in the
art.
[0078] Inactivation by formalin can be performed by mixing the
virus suspension with 37% formaldehyde to a final formaldehyde
concentration of 0.05%. The virus-formaldehyde mixture is mixed by
constant stirring for approximately 24 hours at room temperature.
The inactivated virus mixture is then tested for residual live
virus by assaying for growth on a suitable cell line.
[0079] Inactivation by BEI can be performed by mixing the virus
suspension of the present invention with 0.1 M BEI
(2-bromo-ethylamine in 0.175 N NaOH) to a final BEI concentration
of 1 mM. The virus-BEI mixture is mixed by constant stirring for
approximately 48 hours at room temperature, followed by the
addition of 1.0 M sodium thiosulfate to a final concentration of
0.1 mM. Mixing is continued for an additional two hours. The
inactivated virus mixture is tested for residual live virus by
assaying for growth on a suitable cell line.
[0080] Immunogenic compositions and vaccines of the present
invention can include one or more veterinarily-acceptable carriers.
As used herein, a "veterinarily-acceptable carrier" includes any
and all solvents, dispersion media, coatings, adjuvants,
stabilizing agents, diluents, preservatives, antibacterial and
antifungal agents, isotonic agents, adsorption delaying agents, and
the like. Diluents can include water, saline, dextrose, ethanol,
glycerol, and the like. Isotonic agents can include sodium
chloride, dextrose, mannitol, sorbitol, and lactose, among others
known to those skilled in the art. Stabilizers include albumin,
among others known to the skilled artisan. Preservatives include
merthiolate, among others known to the skilled artisan.
[0081] Adjuvants include, but are not limited to, the RIBI adjuvant
system (Ribi Inc.), alum, aluminum hydroxide gel, oil-in water
emulsions, water-in-oil emulsions such as, e.g., Freund's complete
and incomplete adjuvants, Block co polymer (CytRx, Atlanta Ga.),
SAF-M (Chiron, Emeryville Calif.), AMPHIGEN.RTM. adjuvant, saponin,
Quil A, QS-21 (Cambridge Biotech Inc., Cambridge Mass.), GPI-0100
(Galenica Pharmaceuticals, Inc., Birmingham, Ala.) or other saponin
fractions, monophosphoryl lipid A, Avridine lipid-amine adjuvant,
heat-labile enterotoxin from E. coli (recombinant or otherwise),
cholera toxin, or muramyl dipeptide, among many others known to
those skilled in the art. The amounts and concentrations of
adjuvants and additives useful in the context of the present
invention can readily be determined by the skilled artisan. In one
embodiment, the present invention contemplates immunogenic
compositions and vaccines comprising from about 50 .mu.g to about
2000 .mu.g of adjuvant. In another embodiment adjuvant is included
in an amount from about 100 .mu.g to about 1500 .mu.g, or from
about 250 .mu.g to about 1000 .mu.g, or from about 350 .mu.g to
about 750 .mu.g. In another embodiment, adjuvant is included in an
amount of about 500 .mu.g/2 ml dose of the immunogenic composition
or vaccine.
[0082] The immunogenic compositions and vaccines can also include
antibiotics. Such antibiotics include, but are not limited to,
those from the classes of aminoglycosides, carbapenems,
cephalosporins, glycopeptides, macrolides, penicillins,
polypeptides, quinolones, sulfonamides, and tetracyclines. In one
embodiment, the present invention contemplates immunogenic
compositions and vaccines comprising from about 1 .mu.g/ml to about
60 .mu.g/ml of antibiotic. In another embodiment, the immunogenic
compositions and vaccines comprise from about 5 .mu.g/ml to about
55 .mu.g/ml of antibiotic, or from about 10 .mu.g/ml to about 50
.mu.g/ml of antibiotic, or from about 15 .mu.g/ml to about 45
.mu.g/ml of antibiotic, or from about 20 .mu.g/ml to about 40
.mu.g/ml of antibiotic, or from about 25 .mu.g/ml to about 35
.mu.g/ml of antibiotic. In yet another embodiment, the immunogenic
compositions and vaccines comprise less than about 30 .mu.g/ml of
antibiotic.
[0083] Immunogenic compositions and vaccines of the invention can
further include one or more other immunomodulatory agents such as,
e.g., interleukins, interferons, or other cytokines, suitable
amounts of which can be determined by the skilled artisan.
[0084] Immunogenic compositions and vaccines of the present
invention can include one or more polynucleotide molecules encoding
for a chimeric pestivirus. Either DNA or RNA molecules encoding all
of the chimeric pestivirus genome, or one or more open reading
frames, can be used in immunogenic compositions or vaccines. The
DNA or RNA molecule can be administered absent other agents, or it
can be administered together with an agent facilitating cellular
uptake (e.g., liposomes or cationic lipids). Total polynucleotide
in the immunogenic composition or vaccine will generally be between
about 0.1 .mu.g/ml and about 5.0 mg/ml. In another embodiment, the
total polynucleotide in the immunogenic composition or vaccine will
be from about 1 .mu.g/ml and about 4.0 mg/ml, or from about 10
.mu.g/ml and about 3.0 mg/ml, or from about 100 .mu.g/ml and about
2.0 mg/ml. Vaccines and vaccination procedures that utilize nucleic
acids (DNA or mRNA) have been well described in the art, for
example, U.S. Pat. No. 5,703,055, U.S. Pat. No. 5,580,859, U.S.
Pat. No. 5,589,466, all of which are incorporated herein by
reference.
[0085] Immunogenic compositions and vaccines of the present
invention can also include additional BVDV antigens, for example,
those described in U.S. Pat. No. 6,060,457, U.S. Pat. No.
6,015,795, U.S. Pat. No. 6,001,613, and U.S. Pat. No. 5,593,873,
all of which are herein incorporated by reference.
[0086] In addition to one or more chimeric pestiviruses,
immunogenic compositions and vaccines can include other antigens.
Antigens can be in the form of an inactivated whole or partial
preparation of the microorganism, or in the form of antigenic
molecules obtained by genetic engineering techniques or chemical
synthesis. Other antigens appropriate for use in accordance with
the present invention include, but are not limited to, those
derived from pathogenic bacteria such as Haemophilus somnus,
Haemophilus parasuis, Bordetella bronchiseptica, Bacillus
anthracis, Actinobacillus pleuropneumonie, Pasteurella multocida,
Mannhemia haemolytica, Mycoplasma bovis, Mycobacterium bovis,
Mycobacterium paratuberculosis, Clostridial spp., Streptococcus
uberis, Staphylococcus aureus, Erysipelothrix rhusopathiae,
Chlamydia spp., Brucella spp., Vibrio spp., Salmonella enterica
serovars and Leptospira spp. Antigens can also be derived from
pathogenic fungi such as Candida, protozoa such as Cryptosporidium
parvum, Neospora canium, Toxoplasma gondii, Eimeria spp., Babesia
spp., Giardia spp., or helminths such as Ostertagia, Cooperia,
Haemonchus, and Fasciola. Additional antigens include pathogenic
viruses such as bovine coronavirus, bovine herpesviruses-1,3,6,
bovine parainfluenza virus, bovine respiratory syncytial virus,
bovine leukosis virus, rinderpest virus, foot and mouth disease
virus, rabies virus, and influenza virus.
Forms, Dosages, Routes of Administration
[0087] Immunogenic compositions and vaccines of the present
invention can be administered to animals to induce an effective
immune response against BVDV. Accordingly, the present invention
provides methods of stimulating an effective immune response
against BVDV, by administering to an animal a therapeutically
effective amount of an immunogenic composition or vaccine of the
present invention described herein.
[0088] Immunogenic compositions and vaccines of the present
invention can be made in various forms depending upon the route of
administration. For example, the immunogenic compositions and
vaccines can be made in the form of sterile aqueous solutions or
dispersions suitable for injectable use, or made in lyophilized
forms using freeze-drying techniques. Lyophilized immunogenic
compositions and vaccines are typically maintained at about
4.degree. C., and can be reconstituted in a stabilizing solution,
e.g., saline or and HEPES, with or without adjuvant. Immunogenic
compositions and vaccines can also be made in the form of
suspensions or emulsions.
[0089] Immunogenic compositions and vaccines of the present
invention include a therapeutically effective amount of one or more
of the above-described chimeric pestiviruses. Purified viruses can
be used directly in an immunogenic composition or vaccine, or can
be further attenuated, or inactivated. Typically, an immunogenic
composition or vaccine contains between about 1.times.10.sup.2 and
about 1.times.10.sup.12 virus particles, or between about
1.times.10.sup.3 and about 1.times.10.sup.11 virus particles, or
between about 1.times.10.sup.4 and about 1.times.10.sup.10 virus
particles, or between about 1.times.10.sup.5 and about
1.times.10.sup.9 virus particles, or between about 1.times.10.sup.6
and about 1.times.10.sup.8 virus particles. The precise amount of a
virus in an immunogenic composition or vaccine effective to provide
a protective effect can be determined by a skilled artisan.
[0090] The immunogenic compositions and vaccines generally comprise
a veterinarily-acceptable carrier in a volume of between about 0.5
ml and about 5 ml. In another embodiment the volume of the carrier
is between about 1 ml and about 4 ml, or between about 2 ml and
about 3 ml. In another embodiment, the volume of the carrier is
about 1 ml, or is about 2 ml, or is about 5 ml.
Veterinarily-acceptable carriers suitable for use in immunogenic
compositions and vaccines can be any of those described
hereinabove.
[0091] Those skilled in the art can readily determine whether a
virus needs to be attenuated or inactivated before administration.
In another embodiment of the present invention, a chimeric
pestivirus can be administered directly to an animal without
additional attenuation. The amount of a virus that is
therapeutically effective can vary depending on the particular
virus used, the condition of the animal and/or the degree of
infection, and can be determined by a skilled artisan.
[0092] In accordance with the methods of the present invention, a
single dose can be administered to animals, or, alternatively, two
or more inoculations can take place with intervals of from about
two to about ten weeks. Boosting regimens can be required and the
dosage regimen can be adjusted to provide optimal immunization.
Those skilled in the art can readily determine the optimal
administration regimen.
[0093] Immunogenic compositions and vaccines can be administered
directly into the bloodstream, into muscle, or into an internal
organ. Suitable means for parenteral administration include
intravenous, intraarterial, intraperitoneal, intrathecal,
intraventricular, intraurethral, intrasternal, intracranial,
intramuscular and subcutaneous. Suitable devices for parenteral
administration include needle (including microneedle) injectors,
needle-free injectors and infusion techniques.
[0094] Parenteral formulations are typically aqueous solutions
which can contain excipients such as salts, carbohydrates and
buffering agents (preferably to a pH of from about 3 to about 9, or
from about 4 to about 8, or from about 5 to about 7.5, or from
about 6 to about 7.5, or about 7 to about 7.5), but, for some
applications, they can be more suitably formulated as a sterile
non-aqueous solution or as a dried form to be used in conjunction
with a suitable vehicle such as sterile, pyrogen-free water.
[0095] The preparation of parenteral formulations under sterile
conditions, for example, by lyophilisation, can readily be
accomplished using standard pharmaceutical techniques well known to
those skilled in the art.
[0096] The solubility of compounds used in the preparation of
parenteral solutions can be increased by the use of appropriate
formulation techniques known to the skilled artisan, such as the
incorporation of solubility-enhancing agents including buffers,
salts, surfactants, liposomes, cyclodextrins, and the like.
[0097] Formulations for parenteral administration can be formulated
to be immediate and/or modified release. Modified release
formulations include delayed, sustained, pulsed, controlled,
targeted and programmed release. Thus compounds of the invention
can be formulated as a solid, semi-solid, or thixotropic liquid for
administration as an implanted depot providing modified release of
the active compound. Examples of such formulations include
drug-coated stents and poly(dl-lactic-coglycolic)acid (PGLA)
microspheres.
[0098] Immunogenic compositions and vaccines of the present
invention can also be administered topically to the skin or mucosa,
that is, dermally or transdermally. Typical formulations for this
purpose include gels, hydrogels, lotions, solutions, creams,
ointments, dusting powders, dressings, foams, films, skin patches,
wafers, implants, sponges, fibres, bandages and microemulsions.
Liposomes can also be used. Typical carriers include alcohol,
water, mineral oil, liquid petrolatum, white petrolatum, glycerin,
polyethylene glycol and propylene glycol. Penetration enhancers can
be incorporated. See, for example, Finnin and Morgan, J. Pharm Sci,
88 (10):955-958 (1999).
[0099] Other means of topical administration include delivery by
electroporation, iontophoresis, phonophoresis, sonophoresis and
microneedle or needle-free (e.g. Powderject.TM., Bioject.TM., etc.)
injection.
[0100] Formulations for topical administration can be formulated to
be immediate and/or modified release. Modified release formulations
include delayed, sustained, pulsed, controlled, targeted and
programmed release.
[0101] Immunogenic compositions and vaccines can also be
administered intranasally or by inhalation, typically in the form
of a dry powder (either alone or as a mixture, for example, in a
dry blend with lactose, or as a mixed component particle, for
example, mixed with phospholipids, such as phosphatidylcholine)
from a dry powder inhaler or as an aerosol spray from a pressurized
container, pump, spray, atomizer (preferably an atomizer using
electrohydrodynamics to produce a fine mist), or nebulizer, with or
without the use of a suitable propellant, such as
1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane. For
intranasal use, the powder can comprise a bioadhesive agent, for
example, chitosan or cyclodextrin.
[0102] The pressurized container, pump, spray, atomizer, or
nebulizer contains a solution or suspension of the compound(s) of
the invention comprising, for example, ethanol, aqueous ethanol, or
a suitable alternative agent for dispersing, solubilizing, or
extending release of the active, a propellant(s) as solvent and an
optional surfactant, such as sorbitan trioleate, oleic acid, or an
oligolactic acid.
[0103] Prior to use in a dry powder or suspension formulation, the
drug product is generally micronized to a size suitable for
delivery by inhalation (typically less than about 5 microns). This
can be achieved by any appropriate comminuting method, such as
spiral jet milling, fluid bed jet milling, supercritical fluid
processing to form nanoparticles, high pressure homogenization, or
spray drying.
[0104] Capsules (made, for example, from gelatin or
hydroxypropylmethylcellulose), blisters and cartridges for use in
an inhaler or insufflator can be formulated to contain a powder mix
of the compound of the invention, a suitable powder base such as
lactose or starch and a performance modifier such as l-leucine,
mannitol, or magnesium stearate. The lactose can be anhydrous or in
the form of the monohydrate. Other suitable excipients include
dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose and
trehalose.
[0105] A suitable solution formulation for use in an atomizer using
electrohydrodynamics to produce a fine mist can contain from about
1 .mu.g to about 20 mg of the compound of the invention per
actuation and the actuation volume can vary from about 1 .mu.l to
about 100 .mu.l. In another embodiment, the amount of compound per
actuation can range from about 100 .mu.g to about 15 mg, or from
about 500 .mu.g to about 10 mg, or from about 1 mg to about 10 mg,
or from about 2.5 .mu.g to about 5 mg. In another embodiment, the
actuation volume can range from about 5 .mu.l to about 75 .mu.l, or
from about 10 .mu.l to about 50 .mu.l, or from about 15 .mu.l to
about 25 .mu.l. A typical formulation can comprise the compound of
the invention, propylene glycol, sterile water, ethanol and sodium
chloride. Alternative solvents which can be used instead of
propylene glycol include glycerol and polyethylene glycol.
[0106] Formulations for inhaled/intranasal administration can be
formulated to be immediate and/or modified release using, for
example, PGLA. Modified release formulations include delayed,
sustained, pulsed, controlled, targeted and programmed release.
[0107] In the case of dry powder inhalers and aerosols, the dosage
unit is generally determined by means of a valve which delivers a
metered amount. Units in accordance with the invention are
typically arranged to administer a metered dose or "puff"
containing from about 10 ng to about 100 .mu.g of the compound of
the invention. In another embodiment, the amount of compound
administered in a metered dose is from about 50 ng to about 75
.mu.g, or from about 100 ng to about 50 .mu.g, or from about 500 ng
to about 25 .mu.g, or from about 750 ng to about 10 .mu.g, or from
about 1 .mu.g to about 5 .mu.g. The overall daily dose will
typically be in the range from about 1 .mu.g to about 100 mg which
can be administered in a single dose or, more usually, as divided
doses throughout the day. In another embodiment, the overall daily
dose can range from about 50 .mu.g to about 75 mg, or from about
100 .mu.g to about 50 mg, or from about 500 .mu.g to about 25 mg,
or from about 750 .mu.g to about 10 mg, or from about 1 mg to about
5 mg.
[0108] Immunogenic compositions and vaccines of the present
invention can also be administered orally or perorally, that is
into a subject's body through or by way of the mouth and involves
swallowing or transport through the oral mucosa (e.g., sublingual
or buccal absorption) or both. Suitable flavors, such as menthol
and levomenthol, or sweeteners, such as saccharin or saccharin
sodium, can be added to those formulations of the invention
intended for oral or peroral administration.
[0109] Immunogenic compositions and vaccines of the present
invention can be administered rectally or vaginally, for example,
in the form of a suppository, pessary, or enema. Cocoa butter is a
traditional suppository base, but various alternatives can be used
as appropriate. Formulations for rectal/vaginal administration can
be formulated to be immediate and/or modified release. Modified
release formulations include delayed, sustained, pulsed,
controlled, targeted and programmed release.
[0110] Immunogenic compositions and vaccines of the present
invention can also be administered directly to the eye or ear,
typically in the form of drops of a micronized suspension or
solution in isotonic, pH-adjusted, sterile saline. Other
formulations suitable for ocular and aural administration include
ointments, biodegradable (e.g. absorbable gel sponges, collagen)
and non-biodegradable (e.g. silicone) implants, wafers, lenses and
particulate or vesicular systems, such as niosomes or liposomes. A
polymer such as crossed-linked polyacrylic acid, polyvinylalcohol,
hyaluronic acid, a cellulosic polymer, for example,
hydroxypropylmethylcellulose, hydroxyethylcellulose, or methyl
cellulose, or a heteropolysaccharide polymer, for example, gelan
gum, can be incorporated together with a preservative, such as
benzalkonium chloride. Such formulations can also be delivered by
iontophoresis.
[0111] Formulations for ocular/aural administration can be
formulated to be immediate and/or modified release. Modified
release formulations include delayed, sustained, pulsed,
controlled, targeted and programmed release.
[0112] The immunogenic compositions and vaccines of the present
invention can be used in the preparation of a medicament for
treating or preventing the spread of bovine viral diarrhea virus
infection in an animal.
[0113] The immunogenic compositions and vaccines of the present
invention can be used in the preparation of a medicament for
administering to an animal, wherein the medicament is a DIVA
pestivirus vaccine comprising a chimeric pestivirus comprising a
bovine viral diarrhea virus which does not express its homologous
E.sup.rns protein, and wherein said chimeric pestivirus expresses a
heterologous E.sup.rns protein derived from another pestivirus, or
a natural, synthetic or genetic variant of said heterologous
E.sup.rns protein. In one embodiment, the chimeric pestivirus has
at least one E.sup.rns epitope which is not present in wild-type
bovine viral diarrhea virus. In another embodiment the chimeric
pestivirus lacks at least one E.sup.rns epitope which is present in
wild-type bovine viral diarrhea virus.
Detection, Diagnostic Methods
[0114] The present invention provides methods of determining the
origin of a pestivirus present in an animal subject.
[0115] Vaccination which utilizes a DIVA vaccine--one which is able
to differentiate infected from vaccinated animals--provides a means
for determining the origin of a pestivirus present in an animal
subject. This differentiation can be accomplished via any of
various diagnostic methods, including but not limited to ELISA,
Western blotting and PCR. These and other methods are readily
recognized and known to one of ordinary skill in the art.
[0116] The chimeric pestiviruses of the present invention can be
distinguished from wild-type BVDV strains in both their genomic
composition and proteins expressed. Such distinction allows for
discrimination between vaccinated and infected animals. For
example, a determination can be made as to whether an animal
testing positive for BVDV in certain laboratory tests carries a
wild-type BVDV strain, or carries a chimeric pestivirus of the
present invention previously obtained through vaccination.
[0117] A variety of assays can be employed for making the
determination. For example, virus can be isolated from the animal
testing positive for BVDV, and nucleic acid-based assays can be
used to determine the presence of a chimeric pestivirus genome,
indicative of prior vaccination. The nucleic acid-based assays
include Southern or Northern blot analysis, PCR, and sequencing.
Alternatively, protein-based assays can be employed. In
protein-based assays, cells or tissues suspected of an infection
can be isolated from the animal testing positive for BVDV. Cellular
extracts can be made from such cells or tissues and can be
subjected to, e.g., Western Blot, using appropriate antibodies
against viral proteins that can distinctively identify the presence
of either the chimeric pestivirus previously inoculated, or
wild-type BVDV.
[0118] The extent and nature of the immune responses induced in the
animal can be assessed by using a variety of techniques. For
example, sera can be collected from the inoculated animals and
tested for the presence or absence of antibodies specific for the
chimeric virus, e.g., in a conventional virus neutralization assay.
Detection of responding cytotoxic T-lymphocytes (CTLs) in lymphoid
tissues can be achieved by assays such as T cell proliferation, as
indicative of the induction of a cellular immune response. The
relevant techniques are well described in the art, e.g., Coligan et
al. Current Protocols in Immunology, John Wiley & Sons Inc.
(1994).
KITS
[0119] Inasmuch as it may be desirable to administer an immunogenic
composition or vaccine in combination with additional compounds,
for example, for the purpose of treating a particular disease or
condition, it is within the scope of the present invention that an
immunogenic composition or vaccine can conveniently be included in,
or combined in, the form of a kit suitable for administration or
co-administration of the compositions.
[0120] Thus, kits of the present invention can comprise one or more
separate pharmaceutical compositions, at least one of which is an
immunogenic composition or vaccine in accordance with the present
invention, and a means for separately retaining said compositions,
such as a container, divided bottle, or divided foil packet. An
example of such a kit is a syringe and needle, and the like. A kit
of the present invention is particularly suitable for administering
different dosage forms, for example, oral or parenteral, for
administering the separate compositions at different dosage
intervals, or for titrating the separate compositions against one
another. To assist one administering a composition of the present
invention, the kit typically comprises directions for
administration.
[0121] Another kit of the present invention can comprise one or
more reagents useful for the detection of and differentiation
between a BVDV-infected animal and a chimeric pestivirus-vaccinated
animal. The kit can include reagents for analyzing a sample for the
presence of whole BVDV, or BVDV polypeptides, epitopes or
polynucleotide sequences which are not present in the chimeric
pestivirus of the immunogenic composition or vaccine.
Alternatively, kits of the present invention can include reagents
for analyzing a sample for the presence of a chimeric pestivirus,
or polypeptides, epitopes or polynucleotide sequences which are not
present in wild-type BVDV. The presence of virus, polypeptides, or
polynucleotide sequences can be determined using antibodies, PCR,
hybridization, and other detection methods known to those of skill
in the art.
[0122] Another kit of the present invention can provide reagents
for the detection of antibodies against particular epitopes. The
epitopes are either present in the chimeric pestivirus of the
present invention and not present in wild type BVDV, or
alternatively, are present in wild-type BVDV and not present in the
chimeric pestivirus of the present invention. Such reagents are
useful for analyzing a sample for the presence of antibodies, and
are readily known and available to one of ordinary skill in the
art. The presence of antibodies can be determined using standard
detection methods known to those of skill in the art.
[0123] In certain embodiments, the kits can include a set of
printed instructions or a label indicating that the kit is useful
for the detection and differentiation of BVDV-infected animals from
chimeric pestivirus-vaccinated animals.
Antibody, Antibodies
[0124] Antibodies can either be monoclonal, polyclonal, or
recombinant. Conveniently, the antibodies can be prepared against
the immunogen or a portion thereof. For example, a synthetic
peptide based on the amino acid sequence of the immunogen, or
prepared recombinantly by cloning techniques or the natural gene
product and/or portions thereof can be isolated and used as the
immunogen. Immunogens can be used to produce antibodies by standard
antibody production technology well known to those skilled in the
art, such as described generally in Harlow and Lane, "Antibodies: A
Laboratory Manual", Cold Spring Harbor Laboratory, Cold Spring
Harbor, N.Y., (1988) and Borrebaeck, "Antibody Engineering--A
Practical Guide", W.H. Freeman and Co. (1992). Antibody fragments
can also be prepared from the antibodies, and include Fab,
F(ab').sub.2, and Fv, by methods known to those skilled in the
art.
[0125] In the production of antibodies, screening for the desired
antibody can be accomplished by standard methods in immunology
known in the art. Techniques not specifically described are
generally followed as in Stites, et al. (eds), "Basic and Clinical
Immunology" (8th Edition), Appleton and Lange, Norwalk, Conn.
(1994) and Mishell and Shiigi (eds), "Selected Methods in Cellular
Immunology", W.H. Freeman and Co., New York (1980). In general,
ELISAs and Western blotting are the preferred types of
immunoassays. Both assays are well known to those skilled in the
art. Both polyclonal and monoclonal antibodies can be used in the
assays. The antibody can be bound to a solid support substrate or
conjugated with a detectable moiety or be both bound and conjugated
as is well known in the art. (For a general discussion of
conjugation of fluorescent or enzymatic moieties, see Johnstone and
Thorpe, "Immunochemistry in Practice", Blackwell Scientific
Publications, Oxford (1982).) The binding of antibodies to a solid
support substrate is also well known in the art. (For a general
discussion, see Harlow and Lane (1988) and Borrebaeck (1992).) The
detectable moieties contemplated for use in the present invention
can include, but are not limited to, fluorescent, metallic,
enzymatic and radioactive markers such as biotin, gold, ferritin,
alkaline phosphatase, b-galactosidase, peroxidase, urease,
fluorescein, rhodamine, tritium, .sup.14C and iodination.
[0126] The present invention is further illustrated by, but by no
means limited to, the following examples.
Example 1. Construction and Serological Characterization of
Chimeric Pestiviruses
[0127] E. coli K12 GM2163 [F-ara-14, leuB6, thi-1, fhuA31, lacY1,
tsx-78, galK2, galT22, supE44, hisG4, rpsL136, (Str.sup.r), xyl-5,
mtl-1, dam13::Tn9(Cam.sup.r), dcm-6, mcrB1,
hsdR2(rk.sup.-mk.sup.-), mcrA] harbors a plasmid containing the
full length genomic cDNA of bovine viral diarrhea virus strain NADL
(BVDV-NADL), obtained from Dr. R. Donis, University of
Nebraska.
[0128] RD cells (bovine testicular cells transformed with SV40;
obtained from Dr. R. Donis) were maintained in OptiMEM supplemented
with 3% horse serum, 1% non-essential amino acids (NEAA) in
modified Eagle's medium (MEM), 2 mM GlutaMax and 10 ug/ml
Gentamicin. BK-6 cells were obtained from Pfizer Global
Manufacturing (PGM). Cells were grown in Dulbecco's modified
Eagles' medium (DMEM) supplemented with 5% horse serum or donor
calf serum (PGM), 2 mM Glutamax, and 1% Antibiotic and Antimycotic.
All medium components except where indicated were purchased from
Invitrogen (Carlsbad, Calif.). All cells were maintained at
37.degree. C. in a 5% CO.sub.2 environment.
[0129] Monoclonal antibody (MAb) 15C5 specific to BVDV E.sup.rns
was purchased from IDEXX (Westbrook, Me.). MAb 20.10.6 against BVDV
NS3 was provided by Dr. E. Dubovi (Cornell University). MAbs WS
363, WS 373 and WS 371, having specificity for the Border Disease
virus (BDV) E.sup.rns protein, were obtained from Veterinary
Laboratories Agency (Surrey, UK). Bovine serum samples #77, #816,
#1281, and #1434 were obtained internally at Pfizer. Chimeric
pestiviruses were generated by replacing the E.sup.rns gene of the
BVDV-NADL strain with the E.sup.rns gene of giraffe (G-E.sup.rns),
reindeer (R-E.sup.rns), or pronghorn antelope (P-E.sup.rns)
pestivirus using an overlapping PCR method. Either PfuUltra.TM. II
fusion HS DNA polymerase (Stratagene; La Jolla, Calif.) or
Platinum.RTM. Taq DNA Polymerase High Fidelity (Invitrogen) was
used. The oligonucleotide primers (with accompanying SEQ ID NOs)
for overlapping PCRs and for generating a full length viral DNA are
listed in Table 1.
TABLE-US-00001 TABLE 1 Oligonucleotide primers used for PCR
amplification SEQ ID Primer Binding Site NO Name Origin Sequences
(5'-3') (underlined sequence) 1 Oligo B-5 T7 + NADL
GTGTTAATACGACTCACTATAG T7 promoter TATACGAGAATTAGAAAAGGC 2 Oligo 84
NADL GGGGGCTGTTAGAGGTCTTCC 3 Oligo 127 G-E.sup.rns + NADL
AATTCCACTGGGTGATGTTCTCTC G-E.sup.rns N-terminus
CCATTGTAACTTGAAACAAAACT 4 Oligo 128 G-E.sup.rns
GAGAACATCACCCAGTGGAA 5 Oligo 129 G-E.sup.rns TGCGTGGGCTCCAAACCATGT
6 Oligo 130 G-E.sup.rns + NADL AACATGGTTTGGAGCCCACGCA G-E.sup.rns
C-terminus GCTTCCCCTTACTGTGATGTCG 7 Oligo 131 R-E.sup.rns + NADL
GGTTCCACTGTGTTATATTCTCTC R-E.sup.rns N-terminus
CCATTGTAACTTGAAACAAAACT 8 Oligo 132 R-E.sup.rns
GAGAATATAACACAGTGGAACC 9 Oligo 133 R-E.sup.rns
TGCATTAGCTCCGAACCACGTT 10 Oligo 134 R-E.sup.rns + NADL
AACGTGGTTCGGAGCTAATGCA R-E.sup.rns C-terminus
GCTTCCCCTTACTGTGATGTCG 11 Oligo 135 P-E.sup.rns + NADL
GGTTCCACTGAGTTATATTCAC P-E.sup.rns N-terminus TCCCATTGTAACTTGAAACA
12 Oligo 136 P-E.sup.rns GTGAATATAACTCAGTGGAACC 13 Oligo 137
P-E.sup.rns TGCCTGTGCCCCAAACCATGT 14 Oligo 138 P-E.sup.rns + NADL
AACATGGTTTGGGGCACAGGCA P-E.sup.rns C-terminus
GCTTCCCCTTACTGTGATGTCG 15 Oligo 175 NADL GTTATCAATAGTAGCCACAGAAT 16
Oligo 177 NADL TCCACCCTCAATCGACGCTAAA 17 Oligo 237 CM5960
CCCTGAGGCCTTCTGTTCTGAT 18 Oligo P7 CM5960 CACTTGTCGGAGGTACTACTACT
19 Oligo P8 CM5960 CTTGTCTATCTTATCTCTTATTGC 20 Oligo P3 CM5960
ACTATCTGAACAGTTGGACAGG 21 Oligo 296-1 T7 + GTGTTAATACGACTCACTATA T7
promoter CM53637 GTATACGAGATTAGCTAAAG 22 Oligo 297 P-
CCAGGTTCCACTGAGTTATATTCAC P-E.sup.rns N-terminus E.sup.rns +
CM53637 TCCTGTTACCAGCTGAAGCAGAA 23 Oligo 298 P-
AACATGGTTTGGGGCACAGGCA P-E.sup.rns C-terminus E.sup.rns + CM53637
GCAAGTCCATACTGTAAAGTG 24 Oligo 299 CM53637
TTAATGCCCTCCCTGTCTCTACCACCT 25 Oligo 300 CM53637
AGGATGAGGATCTAGCAGTGGATCT 26 Oligo 303 CM53637
CCATAGCCATCTGCTCAGACAGTA 27 Oligo 92-1 CM53637
GGGGCTGTCAGAGGCATCCTCTAGTC 28 Oligo 321 CM53637
AGCCACTACACCTGTCACGAGAAG 29 Oligo 250 NADL
CACCATGAAAATAGTGCCCAAAGAATC NADL-C C terminus 30 Oligo 252 NADL
TTAAGCGTATGCTCCAAACCACGTC NADL-E.sup.rns C terminus
[0130] Plasmid containing the full length cDNA of BVDV-NADL was
extracted from dam-E. coli K12 GM2163. The plasmid was methylated
in vitro with dam methyltransferase and S-adenosylmethionine (New
England Biolabs; Ipswich, Mass.). G-E.sup.rns, R-E.sup.rns, and
P-E.sup.rns genes (GenBank accession numbers NC_003678, NC_003677,
and AY781152, respectively) were synthesized and cloned into a
cloning vector.
[0131] For construction of chimeric BVDV-NADL/G-E.sup.rns DNA, a
fragment of BVDV-NADL encoding for the 5'UTR to the 3' end of C
gene was amplified by PCR from methylated plasmid with primers
Oligo B-5 and Oligo 127. The G-E.sup.rns gene was amplified by PCR
from the plasmid DNA containing the G-E.sup.rns gene with Oligo 128
and Oligo 129. A BVDV fragment encoding for E1 to the 3'UTR was
amplified by PCR from methylated plasmid with Oligo 130 and Oligo
84. The PCR products were gel purified using QIAquick Gel
Extraction Kit (Qiagen; Valencia, Calif.). The purified PCR
products were treated with Dpn I and Exonuclease 1 (New England
Biolabs). The treated PCR products were assembled to create a full
length chimeric BVDV-NADL/G-E.sup.rns genome by PCR using Oligo B-5
and Oligo 84.
[0132] For construction of chimeric BVDV-NADL/R-E.sup.rns DNA, a
fragment of BVDV-NADL encoding for the 5'UTR to the 3' end of C
gene was amplified by PCR from methylated plasmid with primers
Oligo B-5 and Oligo 131. The R-E.sup.rns gene was amplified by PCR
from the plasmid containing R-E.sup.rns gene with Oligo 132 and
Oligo 133. A BVDV fragment encoding for E1 to the 3'UTR was
amplified by PCR from methylated plasmid with Oligo 134 and Oligo
84. The PCR products were gel purified with QIAquick Gel Extraction
Kit. The purified PCR products were treated with Dpn I and
Exonuclease 1. The treated PCR products were assembled to create a
full length chimeric BVDV-NADL/R-E.sup.rns genome by PCR with Oligo
B-5 and Oligo 84.
[0133] For construction of chimeric BVDV-NADL/P-E.sup.rns DNA, a
fragment of BVDV-NADL encoding for the 5'UTR to the 3' end of C
gene was amplified by PCR from methylated plasmid with primers
Oligo B-5 and Oligo 135. The P-E.sup.rns gene was amplified by PCR
from the plasmid DNA containing P-E.sup.rns gene with Oligo 136 and
Oligo 137. A BVDV fragment encoding for E1 to the 3'UTR was
amplified by PCR from methylated plasmid with Oligo 138 and Oligo
84. The PCR products were gel purified with QIAquick Gel Extraction
Kit. The purified PCR products were treated with Dpn I and
Exonuclease 1. The treated PCR products were assembled to create a
full length chimeric BVDV-NADL/P-E.sup.rns genome by PCR with Oligo
B-5 and Oligo 84.
[0134] For sequence confirmation of the chimeric E.sup.rns regions,
a fragment corresponding to the 5' UTR to the E1 region of each
assembled full length chimeric genome was amplified by PCR using
Oligo B-5 and Oligo 175, and the PCR products were sequenced and
analyzed.
[0135] Full length viral genomic RNA transcripts were generated
from plasmid containing the full-length cDNA of BVDV-NADL or
chimeric BVDV-NADL/E.sup.rns DNAs using mMessage mMachine T7 Ultra
kit (Ambion; Austin, Tex.). Quality and quantity of each RNA
transcript was determined on an RNA gel and a Nanodrop
spectrophotometer (Nanodrop; Wilmington, Del.). Overnight cultures
of RD cells in wells of 6-well plates were transfected with viral
RNA using Lipofectin reagent (Invitrogen) according to the
manufacturer's instructions. Following transfection, the cells were
incubated at 37.degree. C. for 3 days. The supernatants were
harvested and stored at -80.degree. C.
[0136] Viral RNAs from harvested supernatants were extracted using
MagMax.TM. AI/ND Viral RNA Isolation Kit (Ambion) according to the
manufacturer's instructions. The RNAs were reverse transcribed and
the region of each chimera encoding N.sup.pro to E1 was amplified
using primers Oligo 177 and Oligo 175 (Table 1), and the
ThermoScript.TM. RT-PCR System (Invitrogen) according to the
manufacturer's instructions. The RT-PCR products were then
sequenced.
[0137] Cell monolayers from either a viral RNA transfection or
virus infection were fixed in 80% acetone. BVDV- or BDV-specific
monoclonal antibodies (Mabs) were used in conjunction with the
anti-mouse IgG peroxidase ABC Elite kit (Vector Laboratories;
Burlingame, Calif.). Color was developed using VIP peroxidase
substrate (Vector Laboratories).
[0138] Chimeric virus titers were determined by a limiting dilution
method. Viral samples were 10-fold serially diluted and transferred
to 96-well plates (100 .mu.l per well), with 4-6 replicates per
dilution. 100 .mu.l of a suspension of BK-6 cells were then added
to each well, and the plates incubated at 37.degree. C. for 4-5
days. Virus infection was determined by both cytopathic effect
(CPE) and MAb staining. Virus titers were calculated using the
Spearman-Karber method.
[0139] To obtain the biological clones of each chimera, virus
samples were first diluted 100-fold and followed by a 10-fold
dilution series. 100 .mu.l of the diluted viruses were transferred
to each well of a 96 well plate, 4 replicates per dilution. 100
.mu.l of BK-6 cells were then added to each well, and the plates
incubated at 37.degree. C. for 4 days. The supernatants were
harvested and transferred to new plates and stored at -80.degree.
C. The cells were fixed and stained. The supernatants from wells
containing single virus foci were harvested and expanded as virus
stocks.
[0140] Growth kinetics studies were carried out in T-25 flasks
containing BK-6 cells. When the cells reached approximately 90%
confluency, they were infected with each chimera at MOI of 0.02.
After adsorption for 1 hr, the inoculum was removed. Cells were
washed 3.times. with PBS, and 3 ml of fresh growth medium was then
added. Samples were then collected at various time points from 0 to
144 hrs for titer determinations.
[0141] For the virus neutralization test, frozen stocks of the
three BVDV-NADL/E.sup.rns chimeras, parental BVDV-NADL, and
BVDV-CM5960 (BVDV type I) were diluted in DMEM to about 4,000
TCID.sub.50/ml. Sera from cattle immunized with Bovi-Shield Gold
(Pfizer; New York, N.Y.), with pre-determined titers against both
BVDV type I and II, were 2-fold serially diluted with DMEM. 50
.mu.l of virus (200 TCID.sub.50) were mixed with an equal volume of
diluted cattle serum in 96-well tissue culture plates (4
replicates/dilution), and incubated at 37.degree. C. for 60 min.
100 .mu.l of BK-6 cells were then added to each well, and the
plates were incubated at 37.degree. C. for 3-6 days. Serum negative
for BVDV antibodies was also included in each plate as a control.
End point neutralization titers of the sera were determined by both
CPE and by immunohistochemistry (IHC) at day 3 and day 6.
[0142] Results. Chimeric BVDV-NADL/E.sup.rns DNAs in which the NADL
E.sup.rns gene/protein was replaced by E.sup.rns of giraffe
(G-E.sup.rns), reindeer (R-E.sup.rns) or pronghorn antelope
(P-E.sup.rns) pestivirus, were constructed. Plasmid DNA containing
each of the chimeric E.sup.rns regions was sequenced to confirm
sequence authenticity. The following chimeric pestiviruses were
deposited with the American Type Culture Collection (ATCC.RTM.),
10801 University Blvd., Manassas, Va., 20110, USA on Apr. 2, 2009,
and confirmed viable by the ATCC.RTM. on Apr. 23, 2009:
BVDV-NADL/G-E.sup.rns (PTA-9938), BVDV-NADL/P-E.sup.rns (PTA-9939),
and BVDV-NADL/R-E.sup.rns (PTA-9940).
[0143] BVDV-NADL/E.sup.rns chimeric viruses were rescued from RD
cells after transfection with in vitro-transcribed viral RNA.
Extensive cytopathic effect (CPE) in RD cells was observed 48-72
hours after transfection with BVDV-NADL/G-E.sup.rns or
BVDV-NADL/R-E.sup.rns RNA transcripts. CPE was not obvious with the
BVDV-NADL/P-E.sup.rns virus, however. Culture supernatants were
harvested from each well, and the remaining cells were fixed and
stained with BVDV NS3-specific MAb antibody 20.10.6. Cells infected
with one of the three chimeric pestiviruses were incubated with the
MAb. Viral RNAs were extracted from the harvested supernatants, and
sequenced to confirm the E.sup.rns genes of all three chimeras.
[0144] The three BVDV-NADL/E.sup.rns chimeras were tested for their
reactivity to each of several E.sup.rns MAbs specific for BVDV or
BDV. The results are shown in Table 2. The BVDV-NADL/R-E.sup.rns
chimera reacted to all three BDV E.sup.rns Mabs, while neither
BVDV-NADL/G-E.sup.rns, BVDV-NADL/P-E.sup.rns nor BVDV-NADL parental
virus were recognized by BDV E.sup.rns MAbs. BVDV-NADL/G-E.sup.rns
BVDV-NADL/R-E.sup.rns, and NADL parental virus reacted to a
pan-BVDV E.sup.rns MAb 15C5. MAbs specific to either E.sup.rns of
BDV or BVDV did not react with the BVDV-NADL/P-E.sup.rns
chimera.
TABLE-US-00002 TABLE 2 Reactivity of BVDV-NADL/E.sup.rns chimeras
to MAbs Chimera reactivity BVDV- BVDV- BVDV- NADL/ NADL/ NADL/
BVDV- MAb Specificity G-E.sup.rns R-E.sup.rns P-E.sup.rns NADL WS
371 BDV E.sup.rns - +++ - - WS 373 BDV E.sup.rns - +++ - - WS 363
BDV E.sup.rns - +++ - - 15C5 BVDV E.sup.rns +++ +++ - +++ 20.10.6
Pestivirus +++ +++ ++ +++ NS3
[0145] In order to determine whether the chimeric E.sup.rns
proteins in the viruses had any impact on the recognition of viral
neutralizing epitopes by antibodies from BVDV-vaccinated cattle, a
virus neutralization assay was performed with the three
BVDV-NADL/E.sup.rns chimeras, BVDV-NADL, and BVDV-CM5960 (BVDV type
I). Sera from 4 cows with neutralizing antibody titers ranging from
0 to greater than 40,000 (determined previously against
BVDV-CM5960) were utilized. The results (Table 3) indicate that
titers against all three chimeras were generally comparable to
those for parental BVDV-NADL and BVDV-CM5960. The neutralization
titers against BVDV-NADL/P-E.sup.rns were slightly lower than those
against the other two chimeras, BVDV-NADL and BVDV-CM5960.
TABLE-US-00003 TABLE 3 Neutralization titers of bovine antisera
against BVDV-NADL/E.sup.rns chimeras Neutralization titers BVDV-
BVDV- BVDV- Cattle NADL/ NADL/ NADL/ BVDV- Sera # G-E.sup.rns
R-E.sup.rns P-E.sup.rns NADL CM5960 816 <10 <10 <10 <10
<10 77 320 320 320 160 320 1281 6400 12800 3200 3200 25600 1434
51200 25600 6400 25600 51200
[0146] The three BVDV-NADL/E.sup.rns chimeras were biologically
cloned two times by limiting dilution. Three clones of
BVDV-NADL/G-E.sup.rns, four of BVDV-NADL/R-E.sup.rns, and three of
BVDV-NADL/P-E.sup.rns were obtained. These clones were each
expanded between 1-3 times. Titration results indicated that
expanded BVDV-NADL/G-E.sup.rns clone 1, BVDV-NADL/R-E.sup.rns
clones 3 and 5, and BVDV-NADL/P-E.sup.rns clone 2 yielded the
highest titers.
[0147] Growth kinetics studies were performed with
BVDV-NADL/G-E.sup.rns clone 1, BVDV-NADL/R-E.sup.rns clone 3,
BVDV-NADL/P-E.sup.rns clone 2, and uncloned BVDV-NADL/P-E.sup.rns.
Growth curves generated from these clones were compared to the
parental BVDV-NADL. BVDV-NADL/G-E.sup.rns and BVDV-NADL/R-E.sup.rns
chimeras had growth kinetics similar to the parental BVDV-NADL,
while BVDV-NADL/P-E.sup.rns grew slower and had lower titers at
each time point than the parental virus and other two chimeras.
[0148] Three BVDV-NADL/E.sup.rns chimeric viruses were created, in
which the NADL E.sup.rns gene/protein was replaced by E.sup.rns of
a giraffe, reindeer or pronghorn antelope pestivirus. All three
chimeras were viable and infectious in both RD and BK-6 cells. In
vitro data demonstrated that the chimeric E.sup.rns proteins did
not affect neutralization of the chimeras by antisera from
BVDV-vaccinated cattle. This suggests that neutralizing epitopes on
the chimeric viruses, regardless of where they are located, were
not affected by the E.sup.rns substitutions.
[0149] The chimeric viruses had different growth kinetics and
reacted differently to BVDV or BDV E.sup.rns monoclonal antibodies.
BVDV-NADL/G-E.sup.rns and BVDV-NADL/R-E.sup.rns had similar growth
kinetics to the parental virus, while BVDV-NADL/P-E.sup.rns grew
slower and to a lower titer than the parental virus. Both
BVDV-NADL/G-E.sup.rns and BVDV-NADL/R-E.sup.rns reacted to BVDV
E.sup.rns monoclonal antibody 15C5, while BVDV-NADL/P-E.sup.rns did
not. Sequence comparison results showed that G-E.sup.rns and
R-E.sup.rns had higher sequence similarities to BVDV NADL (75.8%
and 76.2%, respectively) than P-E.sup.rns(59%). These data, taken
together with the MAb reactivity results, suggest that G-E.sup.rns
and R-E.sup.rns may be antigenically more similar to the parental
E.sup.rns than P-E.sup.rns.
Example 2. Construction and Serological Characterization and
Efficacy Testing of Chimeric Pestivirus Vaccine Candidates
[0150] Type 1 BVDV strain CM5960 and Type 2 BVDV strain CM53637
were obtained from Pfizer Global Manufacturing. The viral RNAs were
extracted using MagMax.TM. AI/ND Viral RNA Isolation Kit (Ambion)
according to the manufacturer's instructions. The RNAs were reverse
transcribed to generate cDNAs using ThermoScript.TM. RT-PCR System
(Invitrogen) according to the manufacturer's instructions. Chimeric
pestiviruses were generated by replacing the E.sup.rns gene of
CM5960 and CM53637 with the E.sup.rns gene of pronghorn antelope
pestivirus (P-E.sup.rns) using an overlapping PCR method. The
oligonucleotide primers used for PCRs are listed in Table 1.
[0151] For construction of chimeric CM5960/P-E.sup.rns DNA, a
fragment of CM5960 cDNA between the 5'UTR and the 3' end of C gene
was amplified by PCR from CM5960 cDNA with primers Oligo B-5 and
Oligo 135. The P-E.sup.rns gene was amplified by PCR from the
plasmid DNA containing P-E.sup.rns gene with Oligo 136 and Oligo
137. A third fragment between the beginning of E1 and the 3' end of
E2 was amplified by PCR from CM5960 cDNA with primers Oligo 138 and
Oligo 237.
[0152] The above-described fragments were gel purified using a
QIAquick Gel Extraction Kit (Qiagen), and assembled by PCR to
create one fragment with Oligo B-5 and Oligo 237. A fragment
between E1 region and NS5B region was amplified by PCR from CM5960
cDNAs with primers Oligo P7 and Oligo P8. Another fragment between
NS5A region and the end of 3'UTR was amplified by PCR from CM5960
cDNAs with primers Oligo P3 and Oligo 84. These three fragments
were then gel purified, and assembled by PCR with Oligo B-5 and
Oligo 84 to create a full length chimeric CM5960L/P-E.sup.rns
genome.
[0153] For construction of chimeric CM53637/P-E.sup.rns DNA, a
fragment of CM53637 cDNA between the 5'UTR and the 3' end of C gene
was amplified by PCR from CM53637 cDNA with primers Oligo 296-1 and
Oligo 297. A second fragment between the beginning of E1 and the 3'
end of E2 was amplified by PCR from CM53637 cDNA with primers Oligo
298 and Oligo 303. These two fragments were gel purified, and
together with a fragment encoding for the P-E.sup.rns gene (see
above), were assembled by PCR to create one fragment using Oligo
296-1 and Oligo 303.
[0154] A fragment between E1 region and NS3 region was then
amplified by PCR from CM53637 cDNA with primers Oligo 298 and Oligo
299. Another fragment between NS3 region and the end of 3'UTR was
also amplified by PCR from CM53637 cDNA with primers Oligo 300 and
Oligo 92-1. These two fragments and the one above were gel
purified, and assembled by PCR with Oligo 296-1 and Oligo 92-1 to
create a full length chimeric CM53637/P-E.sup.rns genome.
[0155] Full length viral genomic RNA transcripts were generated
from chimeric CM5960/P-E.sup.rns and chimeric CM53637/P-E.sup.rns
DNAs using mMessage mMachine T7 Ultra kit (Ambion). Quality and
quantity of each RNA transcript was determined on an RNA gel.
Overnight cultures of RD cells in wells of 6-well plates were
transfected with viral RNA using Lipofectin reagent (Invitrogen)
according to the manufacturer's instructions. Following
transfection, the cells were incubated at 37.degree. C. for 3 days.
The cells plus the supernatants were passed one to several times in
RD and/or BK-6 cells. The supernatants were then serially passed in
BK-6 cells. The supernatants were harvested and stored at
-80.degree. C.
[0156] To confirm the identity of rescued recombinant virus, viral
RNAs from harvested supernatants were extracted using MagMax.TM.
AI/ND Viral RNA Isolation Kit (Ambion) according to the
manufacturer's instructions. The RNAs were reverse transcribed
using ThermoScript.TM. RT-PCR System (Invitrogen) according to the
manufacturer's instructions and the region of each chimera between
5' UTR and E2 or p7 was amplified by PCR using primers Oligo B-5
and Oligo 237 (for CM5960/P-E.sup.rns chimera) or Oligo 296-1 and
Oligo 321 (for CM53637/P-E.sup.rns chimera) (Table 1), The RT-PCR
products were then sequenced.
[0157] Cell monolayers from either a viral RNA transfection or
virus infection were fixed in 80% acetone. BVDV specific MAbs were
used in conjunction with the anti-mouse IgG peroxidase ABC Elite
kit (Vector Laboratories) for immunohistochemistry. Color was
developed using VIP peroxidase substrate (Vector Laboratories).
Results.
[0158] Chimeric CM5960/P-E.sup.rns and CM53637/P-E.sup.rns viruses
were constructed and rescued. The 5'UTR to E2 regions, including
the chimeric pronghorn-E.sup.rns regions, were confirmed by
sequencing. Both chimeras were viable and infectious in both RD and
BK-6 cells. Both chimeras were not reactive to BVDV E.sup.rns
specific MAb 15C5, but reactive to BVDV NS3 specific MAb 20.10.6 in
immunohistochemistry staining.
[0159] The sequence for the chimeric pestivirus (BVDV-CM5960 (BVDV
type I)/P-E.sup.rns) is presented in the sequence listing as SEQ ID
NO: 31. The sequence for the chimeric pestivirus (BVDV-CM53637
(BVDV type II)/P-E.sup.rns) is presented in the sequence listing as
SEQ ID NO: 32.
[0160] The CM5960/P-E.sup.rns chimera was biologically cloned by
limited dilution (see above Example 1 for methodology).
Example 3. Efficacy Testing of Chimeric Pestivirus Vaccine
Candidates in a Calf Respiratory Disease Model
[0161] BVDV negative healthy calves are obtained, randomly assigned
to study groups, and maintained under supervision of an attending
veterinarian. The test vaccine is combined with a sterile adjuvant,
and administered by either intramuscular (IM) or subcutaneous (SC)
injection, or by intranasal (IN) inoculation. The vaccine is given
either as one or two doses. Two doses of vaccine are administered,
21 to 28 days apart. The animals are subsequently challenged at 21
to 28 days following the final vaccination with a Type 1 or Type 2
strain of BVDV. Challenge inoculum is given intranasally in a 4 ml
divided dose, 2 ml per nostril. Control groups consisting of
unvaccinated, unchallenged animals and/or unvaccinated, challenged
animals are also maintained throughout the study.
[0162] Clinical parameters are monitored daily, including rectal
temperature, depression, anorexia, and diarrhea. Serum
neutralization titers are determined by a constant-virus,
decreasing-serum assay in bovine cell culture, using serial
dilutions of serum combined with a BVDV Type 1 or 2 strain.
Post-challenge isolation of BVDV in bovine cell culture is
attempted from peripheral blood. A BVDV-positive cell culture is
determined by indirect immunofluorescence. To demonstrate
protection following challenge, a reduction in incidence of
infection is demonstrated in vaccinated groups versus the control
groups.
Example 4. Chimeric Pestivirus Vaccine Efficacy Testing in a
Pregnant Cow-Calf Model
[0163] BVDV-negative cows and heifers of breeding age are obtained
and randomly assigned to a vaccination test group or a placebo
(control) group. Cows are inoculated twice by intramuscular (IM) or
subcutaneous (SC) injection, with either vaccine or placebo, 21 to
28 days apart. Following the second vaccination, all cows receive
an IM prostaglandin injection to synchronize estrus. Cows
displaying estrus are bred by artificial insemination with
certified BVDV-negative semen. At approximately 60 days of
gestation, the pregnancy status of cows is determined by rectal
palpation.
[0164] Approximately 6 weeks later, cows with confirmed pregnancies
are randomly selected from each test group. Each of these cows is
challenged by intranasal inoculation of BVDV Type 1 or 2. Blood
samples are collected on the day of challenge and at multiple
postchallenge intervals for purposes of BVDV isolation.
[0165] Twenty-eight days after challenge, left flank laparotomies
are performed and amniotic fluid is extracted from each cow.
Immediately prior to surgery, a blood sample is collected from each
cow for serum neutralization assays. Following caesarian delivery,
a blood sample is collected from each fetus. Fetuses are then
euthanized, and tissues are aseptically collected for purposes of
BVDV isolation. In cases where spontaneous abortions occur, blood
samples are taken from the dam when abortion is detected and two
weeks later. The paired blood samples and aborted fetuses are
subjected to serologic testing and virus isolation. Vaccine
efficacy is demonstrated by a lack or decrease of fetal infection
and late-term abortion.
Example 5. Diagnostic Assays for Differentiation Between Vaccinated
and Naturally Infected Cattle
[0166] Cattle vaccinated with a vaccine of the present invention
can be compared with cattle naturally infected with a wild type
BVDV. Cattle of various ages are vaccinated with either a live or
inactivated chimeric pestivirus vaccine according to instructions
provided. Serum samples are collected 2-3 weeks or later following
vaccination. To differentiate between cattle which received the
chimeric pestivirus vaccine versus those infected by a field
(wild-type) strain of BVDV, serum samples are tested via a
differential diagnostic assay. The chimeric pestivirus elicits the
production of specific antibodies which bind to the E.sup.rns
protein of the chimeric pestivirus, but not to the E.sup.rns
protein present on wild-type BVDV. In the context of wild-type
BVDV, the opposite is true. Specific antibodies are generated which
recognize the E.sup.rns protein present on wild-type BVDV, but not
the E.sup.rns protein present on the chimeric pestivirus. Methods
of assaying for antibody binding specificity and affinity are well
known in the art, and include but are not limited to immunoassay
formats such as competitive ELISA, direct peptide ELISA, Western
blots, indirect immunofluorescent assays, and the like.
[0167] For a competitive ELISA, whole or partial wild-type or
chimeric pestivirus viral antigens, including the E.sup.rns protein
(naturally, synthetically or recombinantly derived), are used as an
antigen source. Following coating of the ELISA plate with antigen
under alkaline conditions, cattle serum samples and dilutions are
added together with an optimized dilution of a MAb specific for
either E.sup.rns protein of the wild type BVDV or the E.sup.rns
protein of the chimeric pestivirus, and incubated for 30-90 min.
Either horseradish peroxidase or alkaline phosphatase is conjugated
to the MAb to allow for colorimetric detection of binding.
Following washing of the plates, an enzyme-specific chromogenic
substrate is added, and after a final incubation step, the optical
density of each well is measured at a wavelength appropriate for
the substrate used. The degree of inhibition of binding of the
labeled mAb is dependent on the level of antibodies in the cattle
serum that specifically recognize the protein coating the
plate.
[0168] In the case of chimeric E.sup.rns protein (e.g. pronghorn
E.sup.rns) present on the chimeric pestivirus being the test
antigen, a lack of binding by the chimeric pestivirus
E.sup.rns-specific mAb indicates the presence of antibodies in the
cattle serum that recognize the chimeric pestivirus-specific
epitope, indicative of vaccination. In contrast, serum from cattle
not immunized, but naturally infected, will not contain antibodies
which will bind to the chimeric pestivirus E.sup.rns protein
coating the plate. Therefore, the chimeric pestivirus
E.sup.rns-specific mAb will bind to the bound protein, and result
in subsequent color development.
[0169] In the case of E.sup.rns protein present on wild-type BVDV
being the test antigen, a lack of binding by the wild type BVDV
E.sup.rns-specific mAb indicates the presence of antibodies in the
cattle serum that recognize the wild-type BVDV-specific epitope,
indicative of a natural (wild-type) infection. In contrast, serum
from cattle immunized with the chimeric pestivirus vaccine will not
contain antibodies which will bind to the wild-type BVDV E.sup.rns
protein coating the plate. Therefore, the wild type BVDV
E.sup.rns-specific mAb will bind to the bound protein, and result
in subsequent color development.
[0170] For development of such an assay, the following methods were
carried out. First, a recombinant baculovirus expressing BVDV-NADL
E.sup.rns was constructed. A portion of the C protein of BVDV, plus
the full length E.sup.rns gene, were amplified by PCR from a
plasmid containing full length of BVDV-NADL cDNA with primers Oligo
250 (SEQ ID NO: 29; 5'-CACCATGAAAATAGTGCCCAAAGAATC-3') and Oligo
252 (SEQ ID NO: 30; 5'-TTAAGCGTATGCTCCAAACCACGTC-3'). The PCR
product was cloned into pENTR.TM./D-TOPO (Invitrogen) and
transformed into One Shot.RTM. Competent E. coli (Invitrogen)
according to the manufacturer's instructions. The recombinant
plasmid was extracted and the insert was confirmed by sequencing.
This plasmid was designated pENTR-E.sup.rns. pENTR-E.sup.rns and
BaculoDirect.TM. Baculovirus Expression System (Invitrogen) were
used to construct recombinant baculovirus expressing BVDV-NADL
E.sup.rns according to the manufacturer's instructions. The
recombinant baculovirus expressing BVDV-NADL E.sup.rns was
generated, plaque purified, expanded, and stored at both 4.degree.
C. and -80.degree. C. The expression of BVDV-NADL E.sup.rns in the
recombinant baculovirus was confirmed by immunofluorescent staining
and Western blotting against BVDV E.sup.rns specific MAb 15C5
following conventional Western Blot methods.
[0171] For production of the ELISA antigen, SF21 cells in 100 ml
suspension culture were infected with 0.5 ml of the recombinant
baculovirus stock. The cells were harvested after 4 days incubation
at 27.degree. C. The cells were centrifuged at low speed (about 800
g) for 10 min to collect the cells and washed once with PBS. The
cells were lysed with 150 mM NaCl, 50 mM Tris HCl pH 8.0, and 1%
IGEPAL CA-630. The mixture was first incubated on ice for 10
minutes and then at -80.degree. C. for 1 hour. After thawing, the
mixture was clarified by centrifugation at 1000 g for 15 minutes.
The supernatant was further clarified by centrifuge at 8000 g for
20 minutes at 4.degree. C. The final supernatant, designated
Baculo-E.sup.rns lysate, was aliquoted and stored at -80.degree.
C.
[0172] In carrying out the assay, the ELISA plates were coated
overnight at 4.degree. C. with 100 .mu.l/well of MAb WB210
(Veterinary Laboratory Agency; Type 1 BVDV E.sup.rns specific),
diluted 1:1000 in carbonate/bicarbonate buffer (pH 9.0). The next
day, the plates were washed three times and blocked with blocking
buffer (PBS containing 1% casein sodium salt and 0.05% Tween 20) at
37.degree. C. for 1 hour. The plates were subsequently washed three
times with blocking buffer, and 100 .mu.l of Baculo-E.sup.rns
lysate (1:3200 diluted in PBS) was added to each well, and the
plates were incubated at 37.degree. C. for 1 hour. Following three
washes with blocking buffer, 100 .mu.l of undiluted cattle serum
samples were added to the wells, except for one column of wells (to
serve as non-competing 15C5-HRP controls), and incubated at
37.degree. C. for 1 hour. Following three more washes with blocking
buffer, 100 .mu.l of MAb 15C5-HRP conjugate (BVDV E.sup.rns
specific, 1:20,000 diluted in blocking buffer) was added to each
well, and incubated at 37.degree. C. for 1 hour. Following three
washes with blocking buffer, 100 .mu.ll of ABTS substrate
(Peroxidase substrate solutions A+B; KPL, USA) was added to each
well, and incubated at room temperature for 20-60 minutes for color
development. The optical density (OD) was measured at the
wavelength of 405 nm. The percentage of OD reduction for each serum
sample is calculated by following formula:
[1-(OD of Sample/Mean OD of 15C5-HRP Controls)].times.100%.
Results:
[0173] All of the serum samples that tested positive by the virus
neutralization (VN) test had over 82% O.D. reduction, except sample
ID#13851 (Table 4). All of the serum samples that tested negative
by the virus neutralization test had less than 17% O.D. reduction,
except sample ID#5150 (Table 4). The discrepancy might be explained
by the differences in how the assays are carried out, as they are
measuring different antibodies, and the proportion of specific
antibodies varies among animals.
TABLE-US-00004 TABLE 4 BVDV positive and negative serum samples in
a MAb15C5 competition ELISA. O.D. of Average O.D. of Row # Sample
ID Sample No Serum Column % Reduction 1 40021 0.0615 0.907013
93.21950182 2 40014 0.0965 0.907013 89.36068171 3 40422 0.0639
0.907013 92.95489701 4 40372 0.0754 0.907013 91.68699897 5 40222
0.0634 0.907013 93.01002301 6 40152 0.0894 0.907013 90.14347093 7
13461 0.0663 0.907013 92.6902922 8 13851 0.641 0.907013 29.32846607
9 13801 0.1599 0.907013 82.37070472 10 13904 0.073 0.907013
91.95160378 11 40504 0.0625 0.907013 93.10924981 12 40471 0.0914
0.907013 89.92296693 13 35037 0.0639 0.907013 92.95489701 14 13690
0.159 0.907013 82.46993152 15 13797 0.0859 0.907013 90.52935294 16
6127 0.0886 0.907013 90.23167253 17 5138 0.7434 0.907013
18.03866097 18 5139 0.8423 0.907013 7.13473787 19 5141 0.7732
0.907013 14.75315128 20 5142 0.7475 0.907013 17.58662776 21 5144
0.8293 0.907013 8.568013909 22 5145 0.9488 0.907013 -4.607100449 23
5146 0.9451 0.907013 -4.199168038 24 5147 1.0138 0.907013
-11.77348064 25 5148 0.9322 0.907013 -2.7769172 26 5149 0.9794
0.907013 -7.980811741 27 5150 0.1157 0.907013 87.24384325 Rows
1-16: Positive cattle serum samples Rows 17-27: Negative cattle
serum samples All serum samples are used undiluted in the ELISA
[0174] Although the present invention has been described in
considerable detail with reference to certain versions thereof,
other versions are possible. Therefore, the scope of the appended
claims should not be limited to the description of the versions
contained herein.
Sequence CWU 1
1
32143DNAArtificial SequenceT7 + NADL 1gtgttaatac gactcactat
agtatacgag aattagaaaa ggc 43221DNAPestivirusmisc_featureNADL
2gggggctgtt agaggtcttc c 21347DNAArtificial SequenceG-Erns+NADL
3aattccactg ggtgatgttc tctcccattg taacttgaaa caaaact
47420DNAPestivirusmisc_featureG-Erns 4gagaacatca cccagtggaa
20521DNAPestivirusmisc_featureG-Erns 5tgcgtgggct ccaaaccatg t
21644DNAArtificial SequenceG-Erns+NADL 6aacatggttt ggagcccacg
cagcttcccc ttactgtgat gtcg 44747DNAArtificial SequenceR-Erns+NADL
7ggttccactg tgttatattc tctcccattg taacttgaaa caaaact
47822DNAPestivirusmisc_featureR-Erns 8gagaatataa cacagtggaa cc
22922DNAPestivirusmisc_featureR-Erns 9tgcattagct ccgaaccacg tt
221044DNAArtificial SequenceR-Erns+NADL 10aacgtggttc ggagctaatg
cagcttcccc ttactgtgat gtcg 441142DNAArtificial SequenceP-Erns+NADL
11ggttccactg agttatattc actcccattg taacttgaaa ca
421222DNAPestivirusmisc_featureP-Erns 12gtgaatataa ctcagtggaa cc
221321DNAPestivirusmisc_featureP-Erns 13tgcctgtgcc ccaaaccatg t
211444DNAArtificial SequenceP-Erns+NADL 14aacatggttt ggggcacagg
cagcttcccc ttactgtgat gtcg 441523DNAPestivirusmisc_featureNADL
15gttatcaata gtagccacag aat 231622DNAPestivirusmisc_featureNADL
16tccaccctca atcgacgcta aa 221722DNAPestivirusmisc_featureCM5960
17ccctgaggcc ttctgttctg at 221823DNAPestivirusmisc_featureCM5960
18cacttgtcgg aggtactact act 231924DNAPestivirusmisc_featureCM5960
19cttgtctatc ttatctctta ttgc 242022DNAPestivirusmisc_featureCM5960
20actatctgaa cagttggaca gg 222141DNAArtificial SequenceT7+CM53637
21gtgttaatac gactcactat agtatacgag attagctaaa g 412248DNAArtificial
SequenceP-Erns+CM53637 22ccaggttcca ctgagttata ttcactcctg
ttaccagctg aagcagaa 482343DNAArtificial SequenceP-Erns+CM53637
23aacatggttt ggggcacagg cagcaagtcc atactgtaaa gtg
432427DNAPestivirusmisc_featureCM53637 24ttaatgccct ccctgtctct
accacct 272525DNAPestivirusmisc_featureCM53637 25aggatgagga
tctagcagtg gatct 252624DNAPestivirusmisc_featureCM53637
26ccatagccat ctgctcagac agta 242726DNAPestivirusmisc_featureCM53637
27ggggctgtca gaggcatcct ctagtc
262824DNAPestivirusmisc_featureCM53637 28agccactaca cctgtcacga gaag
242927DNAArtificial SequenceNADL 29caccatgaaa atagtgccca aagaatc
273025DNAArtificial SequenceNADL 30ttaagcgtat gctccaaacc acgtc
253112307DNAArtificial SequenceErns chimeric virus 31gtatacgaga
attagaaaag gctctcgtat acgtattggg caattaaaat aataattagg 60cctagggaac
aaaagtcccc ctcagcgaag gccgaaaaga ggctagccat gcccttagta
120ggactagcat aaagaggggg gtagcagcag tggtgagttc gttggatggc
ttaagccctg 180agtacagggt agtcgtcagt ggttcgacgc cttggaataa
aggtctcgag atgccacgtg 240gacgagggca tgcccaaagc acatcttaac
ctgagcgggg gtcgcccagg taaaagcagt 300tctaaccgac tgttacgaat
acagcctgat agggtgctgc agaggccttc tgttctgcta 360ctaaaaatct
ctgctgtaca tggcacatgg agttgatcac aaatgaactt ttatacaaaa
420cttacaaaca aaaacccgtc agggtggaag aacctgttta tgatcaggca
ggtgatccct 480tatttggtga aaggggagca gtccaccctc aatcgacgtt
aaagctccca cacaagagag 540gggaatgcga tgtacccatc aacttggcat
ctttaccaaa aaggggtgac tgcaggtcgg 600gtaatagcag aggacctgtg
agcgggatct acttgaagcc agggccacta ttttaccagg 660actataaggg
tcccgtctat cacagggccc cgctggagct ctttgaagag ggaaccatgt
720gtgaaacgac taaacggata gggagagtaa ctggaagtga cggaaagttg
taccacattt 780atgtgtgtat agatggatgt ataataataa aaagtgccac
aagaagtcac caaagggtgc 840ttaggtgggt ccataatagg cttaactgcc
ctctatgggt cacaagttgc tcagacacga 900aagaagaggg agcaacaaaa
aagaaaacac agaaacccga cagactagag aaggggaaga 960tgaaaatagt
gcccagagaa tccgaaaaag acagcaaaac taaacctccg gatgctacaa
1020tagtggtaga tggagttaaa taccaggtga agaagaaggg aaaaatcaag
agtaagaaca 1080ctcaggacgg cttgtaccat aacaaaaaca aaccgccgga
atcacgtaag aaactggaaa 1140aagcattgct ggcatgggca ataataacta
tagttttgtt tcaagttaca atgggagtga 1200atataactca gtggaacctg
gctgacgaag gcaccgaagg cgtacatagg gtcatgtttg 1260agagagggat
aaatagaagt ttacatggca tatggcccca acagatatgc cacggaatcc
1320caagctacaa ccccaccaac agagagctct cgatgattgt cggaatggtt
gatgcaagca 1380ttagaacaaa ttatacctgc tgtaatctac agagacacga
atggaacaaa catggctggt 1440gcaattggta caacatcata ccatggatta
aggtgatgaa ctacagccag aggaacctca 1500ctgaaggcac atatggcaaa
gagtgtgccg taacgtgtag gcacgacagc atattagaca 1560tcaatatagt
cactcaggcc cgcaatcaac ccacaatgtt aaccgggtgc aaaataggaa
1620agaacttttc gttctcaggt gaaattagag aaaaaccatg taattatgat
atccaaccag 1680aggaaatact acatttgcca cacgaatgtg gggagtggta
tagtgaaata agccaccagg 1740cggtcgacat gatcactaat gggttggagg
cctctagaaa ttcagcagcc aaagtcttga 1800gttggatagg gcgcaaattg
gaaaggatag gaaagagagc acaagcaaaa tcaaaaacat 1860ggtttggggc
acaggcagct tccccctact gtgatgtcga tcgaaagatt ggctacatat
1920ggtatacaaa aaattgtacc cctgcctgct tgcccaagaa cacaaaaatt
gtcggccctg 1980ggaagtttga caccaacgca gaggacggca agatactaca
tgagatgggg ggccacttgt 2040cggaggtact actactttct ttagtggtgc
tgtccgactt cgcaccggaa acagccagcg 2100caatgtacct aatcctacat
ttttccatcc cacaaagtca cgttgacata atggaatgtg 2160ataagaccca
gttgaacctc acagtggagc ttacaacagc tgatgtaata ccaggatcag
2220tctggaacct aggcaagtgg gtatgtataa gaccaaattg gtggccttat
gagacaactg 2280tggtgttggc atttgaagag gtgagccagg tggtgaagtt
agtgttgagg gcactcagag 2340atttgacacg catttggaac gctgcaacaa
ctactgcttt cttaatatgc cttgttaaga 2400tagtcagggg ccagatggta
cagggcattc tgtggctact actgataaca ggggtacaag 2460gggacttgca
ttgcaaacct gaattctcat atgccatagc aagggatgaa agaattggtc
2520aactgggggc tgaaggcctt actaccactt ggaaggatta ctcgcctgaa
atgaaactgg 2580aagacacaat ggtcatagct tggtgcaaag atggtaagtt
tacgtacctc ccaaggtgca 2640cgagagaaac cagatatctc gcgatcttgc
atacaagggc cttaccgacc agtgtggtat 2700tcaaaaaact ttttgatggg
cgaaagcaag aggatgtagt cgaaatggac gacaactttg 2760aatttggact
ctgcccatgt gatgccaaac ccatagtaag agggaaattc aatacaacgc
2820tgctgaacgg accggccttc cagatggtat gccccatagg atggacaggg
actgtaagct 2880gtatgtcatt caatatggac accttagcca caaccgtgat
acggacatat agaaggtcca 2940aaccatttcc tcataggcaa ggctgtatca
cccaaaagac tctgggggag gatctccata 3000actgcatcct cggaggaaat
tggacttgtg tgcctggaga cgtgctatta tacaaagggg 3060gctctattga
atcctgcaag tggtgtggtt atcaatttaa agagagcgag ggactaccac
3120actaccccat tggcaagtgt agattagaga atgagactgg ttacagacta
gtagacgata 3180cctcttgtaa tagagaaggt gtggccatag taccacaagg
gacattacgg tgcaagatag 3240gaaaaactac tatacaggtc atagctatgg
ataccaaact cgggcctatg ccttgcagac 3300catatgaaat aatatcaagt
gaggggcctg tagaaaggac agcgtgtacc ttcaactaca 3360ctaaaacatt
aaaaaataag tattttgagc ccagagacag ctacttccag caatacatgc
3420taaaaggaga gtatcaatac tggtttgacc tggaggtaac cgaccatcac
cgggattact 3480ttgccgagtc catattagtg gtggtggtag ccctcctggg
tggcagatat gtactttggt 3540tactagttac atacatggtc ttatcagaac
agaaggcctc agggactcag tatggagcag 3600gggaagtagt gatgatgggc
aacttgctaa cccataatga cattgaagtg gtgacatact 3660tcttgctgtt
gtacctactg ctgagggaag agagcgtaaa gaagtgggtc ttacttttat
3720accacatctt agtgtcacac ccaatcaaat ctgtaactgt gatcctattg
atgattgggg 3780atgtggtaaa ggcagactca gggggccaag ggtactttgg
gcaaatagac ctctgtttta 3840caatagttgt actaatcatc ataggtttaa
tcatagccag gcgtgaccca actatagtgc 3900cactagtaac aataatggca
gcactgaggg tcactggatt gacctaccag cctggagttg 3960acgtcgctat
ggcagtcatg accataaccc tactgatggt tagctatgtg acagattact
4020ttagatataa aagatggtta cagtgcgttc tcagcctggt gtcaggggtg
ttcttgataa 4080gaagcctaat gcacctaggt agaatagagg tgccagaggt
aaccatccca aactggagac 4140cactaacttt aatactgtta tatttgatct
caacaacaat tgtaacaatg tggaaggttg 4200acatcgctgg cttgttgttg
caatgcctgc ctatcttatt actggccaca accttgtggg 4260ccgacttctt
aaccctcata ctgatcctgc ctacctatga attggttaaa ttatactacc
4320tgaaaactgt taggactgat atagaaagaa gttggccagg ggggatagac
tgtacaagag 4380ttgactccat ctacgacatt gatgagagtg gagagggcgt
atatctcttt ccatcaaggc 4440agaaaggaca gaggagcttt tccatactct
tgccccttgt caaagcaaca ctgataagtt 4500gcgtcagcag taaatggcag
ctaatataca tgagttacct aactttggac tttatgtact 4560acatgcacag
gaaagttata gaagagatat caggaggcac caacatgata tccaggttag
4620tagcggcact catagagctg aactggtcca tggaagaaga ggagagcaaa
ggcctaaaga 4680agttttatct attatctgga aggttgagaa acctaataat
aaaacataaa gtaagaaatg 4740agaccgtggc ttcttggtac ggggaggagg
aagtctacgg tatgccaaag atcatgacaa 4800taatcaaggc cagtacgctg
agtaagagca agcactgcat gatatgcact gtatgtgaga 4860gccgagagtg
gaaaggcggc acctgcccaa aatgtggacg ccatgggaag ccgataatgt
4920gtgggatgtc gctagcggat tttgaagaaa gacactataa aagaatcttt
ataagggaag 4980gtaactttga gggtcctttc aggcaagaat acaatggctt
tgtacaatat accgctaggg 5040ggcaattact tgtgagaaac ttgcccgtac
tggcaactaa agtaaaaatg ctcatggtag 5100gcaaccttgg agaagaaatt
ggtgatctgg aacatcttgg gtggatccta agggggcctg 5160ccgtgtgtaa
gaagatcaca gagcacgaaa aatgccacat caatatactg gataaactaa
5220ctgcattttt cgggatcatg ccgaggggga ctacacccag agccccggtg
aggttcccta 5280cgagcttact aaaagtgagg aggggcctgg agactggctg
ggcttacaca caccaaggtg 5340ggataagttc agtcgaccat gtaaccgccg
gaaaagacct attggtctgt gacagcatgg 5400gacggactag agtggtttgc
caaagcaaca acaggttgac cgatgagaca gaatatggcg 5460tcaagactga
ctcaggatgc ccagacggtg ccagatgtta tgtgttaaat ccagaggctg
5520tcaacatatc aggatccaag ggggcagtcg tccacctcca aaagacaggt
ggagaattca 5580cgtgtgtcac cgcatcaggc acaccggcct ttttcgacct
aaaaaacttg aaaggatggt 5640caggattgcc tatattcgaa gcctccagcg
ggagggtggt tggcagagtc aaagtaggga 5700agaatgaaga gtctaaacct
acaaaaataa tgagtggaat ccagaccgtc tcaaagaaca 5760cagcagatct
aactgagatg gtcaagaaga taaccagcat gaacagggga gacttcaagc
5820agattacttt ggcaacaggg gcaggaaaaa ccacagaact cccaaaagca
gttatagagg 5880aaataggaag acacaagaga gtattagttc ttataccatt
aagggcagcg gcagagtcag 5940tttaccagta tatgagatta aaacacccaa
gcatctcttt taacctaagg ataggggaca 6000tgaaagaggg ggacatggca
acggggataa cctatgcatc atacgggtac ttctgccaaa 6060tgccccaacc
aaagctcaga gctgctatgg tagaatactc atacatattc ttagatgaat
6120accattgtgc cactcctgaa caactggcaa ttatcggaaa gatccacaga
ttttcagaga 6180gtataagagt cgtcgccatg actgccacgc cggcagggtc
ggtgaccaca acaggtcaaa 6240agcacccaat agaggaattc atagcccccg
aggtaatgaa aggggaggat cttggtagtc 6300agttccttga tatagcaggg
ttaaaaatac cagtggatga gatgaaaggt aatatgttgg 6360tttttgtacc
cacgagaaac atggcagtag aggtggcaaa gaagctaaaa gctaagggct
6420ataattctgg atactattac agtggagagg atccagccaa tctgagagtt
gtaacatcgc 6480agtctcccta tgtaatcgtg gccacaaatg ctattgaatc
aggagtgaca ctaccagatt 6540tggacacggt tgtagacacg gggctgaaat
gtgaaaagag ggtgagggta tcatcaaaga 6600tacccttcat cgtaacaggt
cttaagagga tggccgtgac tgtgggtgag caggctcagc 6660gtaggggcag
agtaggtaga atgaaacccg ggagatatta tagaagccag gaaacagcaa
6720ccgggtcaaa ggactaccac tatgacctct tgcaggcaca aagatacggg
attgaggatg 6780gaatcaacgt aacgaagtcc tttagggaga tgaattacga
ttggagccta tacgaggagg 6840acagcctact aataacccag ttggaaatac
taaataatct actcatctca gaagacttgc 6900cagccgctgt taagaatata
atggccagga cagatcaccc agagccaatc caacttgcat 6960acaacagcta
tgaagtccag gtcccggtcc tgttcccaaa aataaggaat ggagaagtca
7020cagacaccta cgaaaattac tcgtttctaa acgccagaaa gttaggggag
gatgtacccg 7080tgtatatcta tgccactgaa gatgaggatc tggcagttga
cctcttaggg ctagactggc 7140cagatcctgg gaaccagcag gtagtggaga
ctggcaaagc actgaagcaa gtgaccgggt 7200tgtcctcggc tgaaaatgcc
ctactagtgg ctttatttgg gtacgtaggt tatcaggctc 7260tctcaaagag
gcatgtccca atgataacag acatatatac catcgaggac cagagactag
7320aagacaccac ccacctccag tatgcaccca acgccataaa aaccgaaggg
acagagactg 7380aactgaaaga actggcgtcg ggtgacgtgg aaaaaatcat
gggagtcatt tcagattatg 7440cagccggggg actggagttt gtgaaatccc
aagcagaaaa gataaaaaca gcacctttgt 7500ttaaagaaaa cgtagaagct
gcaaaagggt acgtccaaaa attcattgac tcattaattg 7560aaaataaaga
tgcaataatc agatatggtt tgtggggaac acacactgca ctatacaaaa
7620gcatagctgc aagactggga cacgaaacag cgtttgccac actggtgtta
aaatggctag 7680cttttggagg ggaatcagtg ccagaccaca tcaagcagac
ggcagttgat ttagtggtct 7740attatgtgat gaataagcct tccttcccag
gcgacaccga aacacagcaa gaagggaggc 7800gattcgtcgc tagcctgttc
atctccgcac tggcaaccta cacatacaaa acttggaatt 7860accacaatct
ctctaaagtg gtggaaccag ccttggctta cctcccctat gctaccagcg
7920cattaaaaat gttcacccca acgcggctag agagcgtggt gatactgagc
accacgatat 7980acaaaacata cctctccata aggaagggga agagtgatgg
attgctgggc acggggatca 8040gtgcagccat ggaaatcctg tcacaaaacc
cagtgtcggt gggtatatct gtgatgttgg 8100gggtaggggc cattgctgcg
cacaacgcta ttgagtccag tgaacagaaa aggaccctac 8160ttatgaaggt
gttcgtaaag aacttcttgg atcaggctgc aacggatgag ctggtaaaag
8220aaaacccaga gaaaattata atggccttat ttgaagcagt ccagacaatt
ggtaaccccc 8280tgagactaat ataccacctg tatggggttt actacaaagg
ttgggaggcc aaggaactat 8340ctgagaggac agcaggcaga aacttattca
cattgataat gtttgaagcc ttcgagttat 8400tagggatgga ctcagaagga
aaaataagga acctgtccgg aaattacatc ttggatctga 8460tatacggcct
acacaagcag atcaacagag ggctgaagaa aatagtactg gggtgggctc
8520ctgcaccctt tagttgtgac tggaccccta gcgacgagag gatcagattg
ccaacagaca 8580actatttgag ggtagaaacc aggtgcccat gtggttatga
gatgaaagcg ttcaaaaatg 8640taggtggcaa gcttaccaaa gtggaggaga
gcgggccttt cctatgtaga aacagacctg 8700gtaggggacc agtcaactac
agagtcacca agtattacga tgacaacctc agagagataa 8760aaccggtagc
aaagttggaa ggacaggtgg agcactacta taaaggggtc acagcaaaaa
8820ttgactacag taaaggaaaa acgctcttgg ctactgacaa gtgggaggtg
gaacatggtg 8880tcatgaccag gttagctaag agatatactg gggttgggtt
caatggtgca tacttaggtg 8940atgagcccaa tcaccgtgat ctagtggaga
ggaactgtgc gactataacc aaaaacacag 9000tacagtttct aaaaatgaag
aaggggtgtg cattcaccta tgacctgacc atctccaatc 9060tgaccaggct
tattgaacta gtacacagga acaatcttga agagaaggaa atacccaccg
9120ttacagtcac tacatggcta gcttacacct tcgtgaatga agacgtaggg
actataaaac 9180cagtactagg agagagggta atccccgacc ctgtagttga
tgtcaactta caaccagagg 9240tccaagtgga tacatcagag gtcgggatca
caataattgg aagggaaacc ctgatgacaa 9300cgggggtgac acctgtattg
gaaaaagtag agcctgacgc tagcaacaac caaagctcag 9360tgaagattgg
gttggataag ggtaattacc cagggcctgg aatacagaca catacactaa
9420cagaagaaat acacgacagg gatgcaagac ccttcatcat gatcctgggc
tcaaagaatt 9480ccatgtcaaa tagggcaaag actgctagaa acataaatct
gtacacagga aatgacccca 9540gggaaataag agacttgatg gctgcagggc
gcatgttagt agtagcactg agggatgtcg 9600accctgagct ttctgaaatg
gtcgacttca aggggacctt cttagatagg gaggccctgg 9660aggctctaag
tctcgggcaa cctaaaccta agcaggtcac caaggcagct attagggatt
9720tgattgaaca ggaaaaacag gtggagatcc ctaactggtt tacatcagat
gacccagtat 9780ttttggaagt ggccataaga aatgataagt actacttagt
aggagatgtt ggagaggtaa 9840aagatcaagc taaaacactt ggggccacgg
atcagacaag aattgtaaag gaggtaggct 9900caaggacgta taccatgaag
ctatctagtt ggttcctcca agcatcaaaa aaacagataa 9960gtttaactcc
actgtttgag gaattgttgt tacggtgccc acctgcaact aagagcaata
10020aggggcacat ggcatcagct taccaattgg cacagggtaa ctgggagccc
ctcggttgcg 10080gggtgcacct aggtaccata ccagctagaa gggtgaagat
acacccatat gaagcttacc 10140tgaggttgaa agatttttta gaagaagaag
agaagaaacc tagggttaag gatacagtaa 10200taagagagca caacaaatgg
atacttaaaa aaataaggtt tcaaggaaac ctcaacacca 10260agaaaatgct
caaccccggg aaactatctg aacagttgga cagggagggg cgcaaaagga
10320acatctacaa ccaccagatt ggtaccataa tgtcaagtgc aggcataagg
ctggagaaat 10380tgccaatagt aagggcccaa accgacacta aaacctttca
tgaggcaata agagataaga 10440tagacaagag tgagaaccgg caaaatccag
aattgcacaa caaattgttg gagatttttc 10500acacaatagc ccaacccgcc
ctgaaacaca cttacggtga ggtgacgtgg gagcaacttg 10560aggcagggat
aaataaaaaa ggggcagcag gctttctgga gaagaagaac atcggggaag
10620tattggattc agaaaaacac ctggtggaac aattggtcag ggatctgaag
gccgggagaa 10680agataaaata ttatgaaact gcaataccaa aaaatgagaa
aagagatgtc agcgatgact 10740ggcaggcagg ggacctggtg gatgagaaga
ggccaagagt tattcaatac cctgaagcca 10800agacaaggct agccatcact
aaggtcatgt ataactgggt gaaacagcag cccgttgtga 10860ttccaggata
tgaaggaaag acccctttgt tcaacatctt tgataaagtg agaaaggaat
10920gggacttgtt caatgagcca gtggccgtaa gttttgacac caaagcctgg
gacacacaag 10980tgactagtag ggatctgcaa cttatcggag aaatccagaa
atattactat aggaaggagt 11040ggcacaagtt cattgacacc atcaccgacc
acatgacaga agtgccagtt ataacagcag 11100atggtgaagt atatataaga
aatgggcaga gaggtagtgg ccaaccagac acaagtgcag 11160gcaacagcat
gttaaatgtc ctaacaatga tgtacgcttt ctgcgaaagc acaggggtcc
11220cgtacaagag tttcaacagg gtggcaagga tccatgtctg tggggatgat
ggcttcttaa 11280taactgaaaa agggttaggg ctgaaatttg ctaacaaagg
gatgcagatt cttcacgaag 11340caggcaaacc tcagaagata acggaagggg
aaaagatgaa agttgcctat agatttgagg 11400acatagagtt ctgttcccat
accccagtcc ctgttaggtg gtccgacaat accagtagtc 11460acatggccgg
gagagacacc gctgtgatac tatcaaagat ggctacaaga ttggattcaa
11520atggagagag gggtaccaca gcatatgaaa aagcggtagc cttcagtttc
ttgctgatgt 11580attcctggaa cccgcttgtt aggaggattt gcctgttggt
actttcgcaa cagccagaga 11640cagacccatc caaacaggcc acttattatt
acaaaggtga tccaataggg gcctataaag 11700atgtgatagg tcggaatcta
agtgaactaa agagaacagg cttcgagaaa ttggcaaatc 11760taaacctaag
cctgtccaca ttagggatct ggactaagca cacaagcaaa agaataatta
11820atgactgtgt tgccattggg aaagaagaag gcaactggct agttaacgcc
gacaggctga 11880tatccagcaa aactggccac ttatacatac ctgataaggg
ctttacatta caaggaaagc 11940attatgagca actacagcta agaacagaga
caaaaccggt catgggggtc gggactgaga 12000gatacaagtt gggtcccata
gtcaatctgc tgctgagaag gttgaaagtt ctgctcatga 12060cggccgtcgg
tgccagcagc tgagacaagt gtatatattg taaataaatt
aacccatgta 12120catattgtat ataaatatag ttgggatcgt ccacctcaag
aagacgacac acccaacacg 12180cacagctaaa cagtagttaa gattatctac
ctcaagataa cactacattt aatgcacaca 12240gcactttagc tgtatgagga
tacgcccgac gtctacagtt ggactaggga agacctctaa 12300cagcccc
123073212663DNAArtificial SequenceErns chimeric virus 32gtatacgaga
ttagctaaag tactcgtata cggattggac gtcaacaaat ttttttaatt 60ggcaacgtag
ggaactttcc cctcagcgaa ggccgaaaag aggctagcca tgcccttagt
120aggactagca aaaatagggg actagcggta gcagtgagtt cattggatgg
ccgaacccct 180gagtacaggg gagtcgtcaa tggttcgaca ctccattggt
tgaggagtct cgagatgcca 240tgtggacgag ggcatgccca cggcacatct
taacccatgc gggggttgca tgggtgaaag 300cgctattcat ggcgttatgg
acacagcctg atagggtgta gcagagacct gctattccgc 360tagtaaaaac
tctgctgtac atggcacatg gagttgtttt caaatgaact tttatacaaa
420acatataaac aaaaaccagc aggcgtcgtg gaacctgttt acgacgtcaa
cgggcgtcca 480ctgtttggag agagcagtga cttgcacccg cagtccacgc
taaaactacc acaccaacga 540ggtagtgcca acatcctgac caatgctagg
tccctaccgc ggaaaggtga ctgccggaga 600ggtaatgtgt atggagcggt
gagtggcatc tatatcaagc caggaccgat ctactaccag 660gattatgcgg
agcctgtcta ccatagagcc ccattagaac tatgtaggga ggcaagtatg
720tgcgaaacaa ctaggagagt tggcagagtg accggtagtg atgggaaatt
atatcatatc 780tacatctgca tagatgggtg tatcctcctg aagagggcga
ctaggaatca accagaagtc 840ctaaaatggg tatacaacag attagattgt
cctttatggg tcactagctg ctccgatgaa 900gggagtaaga gtgctacaag
taagaagcag cctaagccag ataggataga aaaaggcaag 960atgaaaatag
ccccaaaaga gacagaaaaa gattgcaaaa ccagaccccc cgacgcgact
1020atagtagtag aaggggttaa gtaccaggtg aagaaaaaag gaaaggtaag
gggaaaaaat 1080actcaagatg ggttgtatca caacaagaat aagccccctg
aatcaagaaa gaaattggaa 1140aaggcactac tagcttgggc catcttggca
gcggttctgc ttcagctggt aacaggagtg 1200aatataactc agtggaacct
ggctgacgaa ggcaccgaag gcgtacatag ggtcatgttt 1260gagagaggga
taaatagaag tttacatggc atatggcccc aacagatatg ccacggaatc
1320ccaagctaca accccaccaa cagagagctc tcgatgattg tcggaatggt
tgatgcaagc 1380attagaacaa attatacctg ctgtaatcta cagagacacg
aatggaacaa acatggctgg 1440tgcaattggt acaacatcat accatggatt
aaggtgatga actacagcca gaggaacctc 1500actgaaggca catatggcaa
agagtgtgcc gtaacgtgta ggcacgacag catattagac 1560atcaatatag
tcactcaggc ccgcaatcaa cccacaatgt taaccgggtg caaaatagga
1620aagaactttt cgttctcagg tgaaattaga gaaaaaccat gtaattatga
tatccaacca 1680gaggaaatac tacatttgcc acacgaatgt ggggagtggt
atagtgaaat aagccaccag 1740gcggtcgaca tgatcactaa tgggttggag
gcctctagaa attcagcagc caaagtcttg 1800agttggatag ggcgcaaatt
ggaaaggata ggaaagagag cacaagcaaa atcaaaaaca 1860tggtttgggg
cacaggcagc aagtccatac tgtaaagtgg agaggaagat cggttacatc
1920tggtatacaa aaaactgcac tccagcttgc cttccaagaa acactaaaat
aataggcccc 1980gggaagtttg ataccaacgc cgaagatgga aaaatactcc
atgagatggg ggggcacctc 2040tcagaatttg tcctattgtc tttggtggtt
ctgtctgact ttgccccaga aaccgcgagt 2100gccatctact tggttctaca
ttttgcgatc ccgcaaaacc acgttgatgt agacacatgc 2160gacaagaacc
agctgaattt aacggtcgca actacagtag cagaggtcat accagggaca
2220gtgtggaacc tagggaagta tgtctgcata agaccagact ggtggccata
tgagacgacg 2280acagtcttcg tcttagagga agcagggcaa gtaatcaaat
tggggctaag ggccatcaga 2340gacttaacta ggatatggaa tgctgccacc
accacagctt tcctaatctt tttagtgaaa 2400gcactaaggg gacaactaat
ccaagggcta ttgtggctga tgctaataac aggagcacag 2460ggtttccctg
aatgcaaaga gggcttccaa tatgccatat ctaaagacag aaaaatgggg
2520ttactgggac cagagagctt aactacaaca tggcacctcc ccaccaaaaa
aatagtggac 2580tccatggtaa gtgtatggtg tgaaggaaaa gacttaaaaa
tattaaaaac gtgcacaaag 2640gaagagaggt acctagtggc tgtgcacgag
agagccttat caaccagtgc cgagtttatg 2700cagatcagtg atgggacaat
aggcccagac gtgatagata tgcctgatga ctttgagttt 2760ggactctgcc
cttgtgactc aaaaccagtg ataaagggca aatttaatgc cagcttactg
2820aatggaccag ctttccagat ggtatgccca caggggtgga ctggtacagt
agaatgcacc 2880ctagtgaacc aagacacctt ggacacaact gtcattagga
catatagaag aactacccca 2940tttcagcgga gaaaatggtg tacctatgaa
aaaataatag gggaagatat ccatgaatgc 3000attctaggtg gaaactggac
atgcataacc ggtggccaca gcgggttgaa agacggacct 3060atcaagaagt
gtaagtggtg tggctatgac ttcgtcaact cagagggact accacactac
3120ccaataggca agtgcatgct catcaatgag agtgggtaca ggtatgtaga
tgacacctct 3180tgcgataggg gtggtgtagc catagttcca actggcaccg
taaagtgtag aataggtaac 3240gtcacggtgc aagttatcgc tactaacaat
gatctgggac ccatgccttg cagcccagct 3300gaagtgatag caagtgaagg
accagtggaa aagactgcat gcacattcaa ctattcaagg 3360actctaccta
ataagtatta tgagccaagg gaccggtact tccaacaata catgttaaaa
3420ggggggtggc aatattggtt cgacctggat tctgtagacc accacaaaga
ctacttctca 3480gagttcataa tcatagcagt ggtcgccttg ttgggtggta
agtacgtact atggctcttg 3540ataacataca caatactgtc tgagcagatg
gctatgggcg ctggagtgag tactgaagag 3600atagtcatga taggcaactt
gctgacacac agtgatattg aggttgtggt ctatttcctt 3660cttctgtact
taatagttaa agaggaactg gtgaggaaat gggttatact ggtataccac
3720atccttgtag ctaaccctat gaaaacaact ggggtcatct tactaatgct
agggggagtg 3780gtgaaggcca gcagaatcaa tgctgatgac caaagtgcta
tggacccatg ctttcttctc 3840gtgacaggtg tagtggctgt tttgatgatc
gctagaagag aacctgccac cttaccactg 3900attgtagcat tgctagcaat
aagaacatca ggattcctac tgtccgctag cattgatgta 3960actgtagcag
tagtattaat tgtacttttg ctggctagct acgtaacaga ctactttaga
4020tataaaaagt ggcttcaatt ctcatttagt ctgatagctg gtatctttat
tataaggagc 4080ttgaaacata tcaaccagat ggaggtacca gaaatatcta
tgccaagttg gagacctcta 4140gctcttgtct tcttctatat aacatctaca
gcaataacca ctaattggga cattgactta 4200gcaggcttcc tgctgcaatg
ggcgccagca gtgatcatga tggctaccat gtgggcagac 4260tttttgactc
tgatcatagt cctgcccagt tacgagttat ctaagcttta cttcctaaag
4320aacgtcagga cagacgtgga aaagaactgg ctcggcaagg tgaaatacag
acagatcagt 4380tcagtttatg acatctgtga cagtgaggaa gcagtgtacc
tatttccatc aaggcataag 4440agtggaagca ggccagattt catattaccc
tttttgaaag ccgtgttaat aagctgcatc 4500agcagccaat ggcaaatggt
ttacatttct tacctaatac tggaaatcac atactatatg 4560cacaggaaaa
tcatagatga ggtgtcagga ggagcaaatt ttctatcaag acttatagca
4620gccatcatag aattaaattg ggccatagat gatgaggaat gtaaagggct
gaagaaactg 4680tatctcttgt cagggagagt gaagaattta atagttaaac
ataaggtaag aaatgaagcc 4740gtccacagat ggtttggtga ggaggaaata
tatggggcac ccaaggtgat caccatcata 4800aaagctagta ccctaagtaa
aaacaggcac tgcataatct gcacgatctg tgaagggaaa 4860gaatggaacg
gagccaactg cccaaagtgt ggaagacaag gaaagcccat aacatgtgga
4920atgacactcg cagactttga ggagaaacat tacaaaaaga tatttataag
agaaggacgc 4980caagaagcaa tgaatacgat gatgtgcagc cgatgccagg
gaaagcatag gaggtttgaa 5040acggaccggg aacctaagag tgccagatac
tgtgctgagt gtaataggct gcatcctgct 5100gaggaaggtg acttttgggc
agagtcaagc atgttgggcc tcaaaatcac ctactttgcg 5160ctgatggatg
gaaaggtgta tgatatcaca gagtgggctg gatgccagcg tgtgggaatc
5220tccccagata cccacagagt cccttgtcac atctcatttg gttcacggat
gccaggcacc 5280agtgggcggc agagagctac tccagatgcc cctcctgctg
accttcagga tttcttgagc 5340cggatctttc aagtaccccc aggccagatg
tccagggaag agtataaggg ttacgtccaa 5400tacacagcca gaggacaact
ctttctgagg aacctgccaa ttctagcgac gaagatgaag 5460ctattaatgg
tggggaacct cggcgcagaa gttggcgacc tggaacatct aggatgggta
5520ctgagagggc cagccgtgtg caaaaaaatt accaaccatg agaagtgcca
cgtaaacatc 5580atggataagc taactgcatt ttttggaatc atgcctagag
gcacaacccc tagggcacct 5640gtgaggttcc ccacagcact attgaaagtg
agaagggggc tagagacggg atgggcttac 5700acacaccaag gagggatcag
ctcggtagac catgtcacag ccggaaagga tttactggtg 5760tgtgacagta
tgggcaggac cagggttgtc tgtcatagta acaataagat gactgacgag
5820actgagtatg gcatcaagac cgactcaggg tgccccgaag gcgcgaggtg
ttacgtgcta 5880aacccagaag ctgttaacat ttctggcaca aaaggagcta
tggtacacct ccagaaaact 5940gggggggagt tcacatgtgt cactgcctca
gggaccccgg ctttcttcga tctaaaaaat 6000ctaaaaggct ggtccgggct
gccaattttt gaagcatcca gtggcagggt ggttggtagg 6060gtgaaagtcg
gcaagaatga ggattccaag cccaccaaac taatgagcgg aatccagaca
6120gtgtctaaga gccagacgga cctagcggac atcgtaaaga aattgactag
tatgaacaga 6180ggagagttca aacagataac attagccact ggggcaggaa
aaactacgga actgccaagg 6240tccgttatag aggagatagg gaggcacaaa
agggtcttag tcctgatacc attgagagcg 6300gcagcagagt cagtgtatca
gtatatgaga gtgaagtacc caagtatatc tttcaatttg 6360agaataggag
atatgaagga aggtgatatg gccaccggta tcacttacgc ctcatatggg
6420tacttttgtc agcttcctca gcccaaactg agagctgcca tggtagagta
ttcatatata 6480ttcttagatg agtaccactg tgctacaccc gagcaattag
caataattgg aaagatacac 6540aggtttgctg aaaatcttag agtggtagca
atgacagcaa ccccagctgg aacggtcaca 6600acgactggtc agaaacaccc
tatagaggag ttcatagccc cagaggtgat gaagggtgaa 6660gatctaggta
gtgaatactt ggatattgca gggttgaaga taccgactga agagatgaaa
6720ggcaacatgc tcgtgttcgt gccaactagg aacatggcag tagaaacagc
taagaaattg 6780aaggcaaaag ggtacaactc cggatactat tacagtgggg
agaacccaga aaacttgagg 6840gtggtgacct cacaatcccc gtatgtggta
gtagccacca atgccataga gtcaggtgtg 6900acattaccag acttagacac
agttgtagac actggactaa aatgtgagaa gagggtgagg 6960atatcttcaa
aaatgccctt cattgtaaca ggacttaaga gaatggcagt cacaatagga
7020gagcaagccc agcgcagggg gagagtagga agagtcaagc caggtaggta
ctataggagt 7080caagaaacag cttcagggtc aaaagattac cattacgacc
tactacaagc ccagaggtac 7140ggaatagaag atggaattaa tgtaacaaag
tcattcaggg agatgaacta tgattggagc 7200ctttatgaag aggacagctt
gatgataact caactcgagg tccttaacaa cctccttata 7260tcagaagacc
tgcctgccgc agtgaagaac atcatggccc ggaccgatca cccagaaccc
7320atacaactgg cctataacag ttatgaaaac caagttccag tgctgttccc
aaagatcaaa 7380aatggtgagg tgacagacag ttatgagaat tacacatacc
tcaatgcaag aaaactagga 7440gaggacgtgc cggcgtatgt gtacgccacg
gaggatgagg atctagcagt ggatcttctg 7500ggtatggatt ggccggaccc
aggcaaccaa caggtggtag agacagggag ggcattaaag 7560caagtaactg
gcttatccac agcagaaaat gccctcttga tagccttatt cggttacgtc
7620gggtaccaga cgctttcaaa aaggcacata cccatgatta ctgacatcta
tacacttgaa 7680gaccacagac ttgaggacac aacccacctc cagtttgccc
caaacgctat aaggaccgac 7740ggcaaggact cagagttgaa agaattagct
gtgggagacc ttgataaata tgtggacgca 7800ctggtagact actccaaaca
agggatgaaa tttatcaaag tccaagctga aaaggtcaga 7860gactcccagt
ctacaaagga aggcttgcaa aatattaagg agtatgtgga taagtttata
7920caatcactaa cagagaataa ggaggagatc atcaggtatg gactatgggg
agttcacaca 7980gcactctaca aaagcttggc agcgagactg gggcatgaaa
cagcttttgc aactttagtg 8040gtaaaatggc tggcttttgg gggcgaaacg
gtatctgctc acatcaagca agtagcagtt 8100gatctagtag tatactatat
catcaacaaa ccatcctttc ctggagatac agagacccaa 8160caagagggga
ggaggtttgt ggctagtctt tttatatctg cactagcaac atacacatat
8220aaaacctgga attacaacaa tctgcaacgg gttgtcgaac ctgccttagc
ttacctccca 8280tatgctacaa gtgccttgaa gttgttcgca cccacaagat
tagagagtgt ggtcatactc 8340agttctacaa tttacaagac atacctctct
ataaggaagg gtaagagcga cggcttgtta 8400ggtacaggca taagtgcagc
catggagatc ctaaaccaaa acccaatctc agtaggtata 8460tctgtgatgc
tgggggtagg tgccatcgcc gcccataatg caatagaatc tagtgaacag
8520aaaagaactt tgctgatgaa ggtctttgta aaaaattttt tggaccaagc
agcgacagat 8580gagctagtca aagagaaccc tgaaaaaata atcatggctc
tatttgaagc agtccagacc 8640ataggaaacc ccctaagact catctaccat
ctgtacgggg tgtactataa ggggtgggaa 8700gcaaaagaac tcgcagagaa
aactgctggc cgcaacttat tcacattgat tatgtttgaa 8760gcctttgagc
ttttaggtat ggactcagaa ggaaagataa gaaacttgtc aggcaactac
8820atactggact taatcttcaa tttgcataat aaattaaaca agggtctcaa
aaaactagtc 8880cttgggtggg ctccagcacc tttcagctgt gattggacac
caagtgatga gaggataagc 8940ttaccccata acaactactt aagggtagaa
accaggtgtc cttgtggcta tgagatgaag 9000gcaataaaaa atgttgctgg
taaattgaca aaagttgaag aaaaggggcc cttcctatgc 9060aggaatagat
tagggagagg acctccaaac ttcaaagtaa caaagttcta tgatgatgac
9120ttgaaagaag tcaagccagt agctaggcta gaaggccagg tggacctcta
ttacaaggga 9180gtaacagcaa agttagacta caacaatggg aaagtactgt
tagctaccaa caagtgggag 9240gtggaccacg ctttcctgac cagattagta
aagaagcaca cagggatagg ttttaaaggt 9300gcatatttgg gtgacagacc
agaccatcaa gatcttgtcg atagagattg tgcaactata 9360acgaagaact
cagtacagtt cctaaaaatg aagaaaggtt gcgctttcac atatgaccta
9420acaatctcta accttgtcag gcttattgaa ctagtccata agaacaattt
acaagaaaga 9480gagatcccca ccgtgacagt aactacttgg cttgcatatt
cttttgtcaa tgaagacctg 9540gggactatca agcctgtatt gggggagaaa
gtcatcccag aaccccccga ggagttgagt 9600ctccaaccca ctgtgggact
agtcaccact gagacagcaa taaccataac aggggaggct 9660gaagtgatga
cgacagggat cacaccagtg gtagagatga aagaagaacc tcagctggac
9720caccagtcaa ctaccctaaa ggtagggtta aaggaagggg aatatccagg
gccaggagtt 9780aaccctaacc atttagtaga ggtgatagat gagaaagatg
acaggccttt tgtcctaatt 9840atcggtaaca aaggttctac ctcgaacaga
gcaagaacgg ccaagaatat acggctgtac 9900aaaggaaaca acccaagaga
gatcagggat ctgatgagcc aaggaagaat attaacggtt 9960gctctaaaag
agttggaccc ggaattaaaa gaattagtag attacaaggg gacctttctc
10020aatagggaag ctttagaagc cctaagctta ggtaagccaa ttaagaggaa
aaccacagca 10080gcaatgatca ggaggttaat agagccagag gttgaggagg
aactaccaga ttggttccaa 10140gcggaagaac ccctattttt ggaagcaaaa
atacagaatg acttatacca cctaattggc 10200agtgttgata gtataaaaag
caaagcaaag gaattagggg ccacagataa cacaaagata 10260gtgaaggaag
tcggggctag gacctatacg atgaaattga gtagctggag cacacaagtt
10320actaaaaaac agatgagttt agcccctctc tttgaagagc tgttattaaa
gtgccctcca 10380tgtagtaaaa tttcaaaggg acatatggtg tcagcatacc
aactggctca aggaaactgg 10440gaacccctcg ggtgtggggt ctatatggga
accataccag ctaggcgtct caagatccac 10500ccttatgagg cttaccttaa
actcaaagag ctgctggaag ttgaatcttc gaggatcacc 10560gcaaaagaat
ccatcataag agaacataac acctggattc tgcggaaagt gagacatgag
10620gggaacctaa gaactaaatc aatgattaac cctgggaaaa tatcagatca
gctatgcaga 10680gacggacaca aaagaaacat atataataag atcataggct
caacaatggc ctctgctggt 10740attaggctgg agaaactgcc agtagtccga
gcccaaactg acacaaccag tttccaccaa 10800gccataagag aaaaaattga
taaaccagaa aacaagcaga cccctgaatt gcatgaagaa 10860ctaatgaagg
ttttcgactg cttaaagatc ccagagctga aggaatcgta tgatgaagtt
10920tcatgggaac aattagaagc aggaataaac cgtaagggtg cagcaggtta
tctagagagt 10980aagaacatag gggaagtgct agacacagag aaacacatag
tagagcagct gatcaaggat 11040ctgaggaagg ggaagaagat taagtactat
gaaacagcca ttcccaagaa tgagaagaga 11100gacgtcagcg acgactggga
agccggagac ttcgttgatg aaaagaaacc aagagtaatc 11160cagtacccgg
acgccaaggt gagactggca attacaaaaa tgatgtacaa atgggtaaag
11220caaaaaccag tggtgatacc cggctatgaa ggaaaaacac cactatttga
catattcaac 11280aaagtgaaga aggaatggga ttcattccag gaccccgtag
cagtgagctt tgacaccaaa 11340gcgtgggata cacaagtcac cagtagagac
ctaatgttga taagggatat ccagaaatat 11400tatttcaaga gaagtacaca
caaattttta gatacaataa cagaacacat ggtagaagta 11460cctgtcatta
cagcagacgg tgaagtttac ataaggaatg gtcagagggg tagtggccaa
11520cccgacacaa gtgctggtaa tagtatgttg aatgtcctaa ccatgatata
tgctttctgt 11580aaaagtacag gcatacctta caggggattc agcagagtgg
caagaatcca tgtgtgtggt 11640gatgatggct ttctgataac agaaagagga
ctggggctga aattctctga gaagggtatg 11700cagatattac atgaggccgg
gaagccccag aaaataactg aaggggacag aatgaaagtg 11760gcatacagat
ttgaggacat cgagttttgt tcccatacac ccgtaccagt cagatgggca
11820gataacacca gtagttacat ggcagggagg agcacagcca ctatactagc
taagatggca 11880accaggttgg attccagcgg agagaggggt agcacagctt
atgagaaggc cgtagccttc 11940agcttccttt tgatgtactc atggaatccc
gtagttagaa ggatctgctt actggtgttg 12000tcacagtttc cagaaatatc
cccatccaaa aacacaatat actactacca aggggatccc 12060atagctgcgt
acagagaagt gataggtaaa cagctgtgtg aactgaaaag aacaggattt
12120gagaagctgg ctggtctgaa tttgagtatg accactctag gcatctggac
aaaacattct 12180agtaaaagac taatccaaga ctgtgtagag ataggtaaga
gagaaggtaa ctggttagtt 12240aatgctgaca gactgattgc aggaaagact
gggaagtttt acatcccaag cactggtgtc 12300actctgttgg gaaaacatta
tgaggaaatt aacttaaagc aaaaggcggc acaaccgccg 12360atagaggggg
ttgacagata taagttgggc cccatagtta atgtaatctt gagaaggctg
12420agggtgatgc tgatgacagt tgccagcgga agctggtaaa tccgtccgga
gcatcgtgcc 12480ctcgctcaag gttttaattg taaatattgt aaatagacag
ctaagatatt tattgtagtt 12540ggatagtaat gtagtgatag tagatacccc
aatttaacac tacctccaat gcactaagca 12600ctttagctgt gtgaggttaa
ctcgacgtcc acggttggac tagaggatgc ctctgacagc 12660ccc 12663
* * * * *